Neurology

University of North Carolina at Chapel Hill, School of Medicine

649 Grants

This is a chronological listing of grants held by this department, with the most recent listed first. New grants appear in this list weekly and contribute related to the department's Research Profile. The source of grants for this application comes directly from your institution.

• 1.

  Maureen Su; James Howard

  Autoimmune mechanisms in a novel Aire-deficient model of peripheral neuropathy

  6/1/2013 - 5/31/2018

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 343,116.00

• 2.

  Rick Meeker; Youmei Xie

  Neurotrophin protection in HIV and aging

  2/1/2013 - 1/31/2017

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 266,000.00

• 3.

  Timothy Gershon

  Glycolytic Metabolism as a Novel Therapeutic Target in Medulloblastoma

  1/1/2013 - 12/31/2014

  Sponsor: American Institute for Cancer Research (AICR)

  Funding: $ 165,000.00

• 4.

  Silva Markovic-Plese

  The Role of IL-11 in the Development of the Autoimmune Response in MS

  10/1/2012 - 9/30/2013

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 99,999.00

• 5.

  Deborah Porterfield; Gary Asher; Susan Gaylord; John Mann

  UNC-CH Integrative Medicine Program

  9/30/2012 - 9/29/2014

  Sponsor: Bureau of Health Professions (BHP)

  Funding: $ 150,000.00

• 6.

  Dinggang Shen; Daniel Kaufer; Amir Khandani; J Smith; Pew Thian Yap; Hongtu Zhu

  Quantifying Brain Abnormality by Multimodality Neuroimage Analysis

  8/1/2012 - 5/31/2015

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 413,404.00

• 7.

  Adam Jacks; Katarina Haley; Heidi Roth

  Auditory masking effects on speech fluency in aphasia and apraxia of speech

  7/1/2012 - 6/30/2015

  Sponsor: NIH National Institute on Deafness and Other Communication Disorders (NIDCD)

  Funding: $ 143,140.00

• 8.

  Daniel Kaufer; Carla Gene Rapp

  Optimizing the Assessment of Neuropsychiatric Symptoms In Clinical Practice

  7/1/2012 - 6/30/2013

  Sponsor: Alzheimers North Carolina Inc.

  Funding: $ 48,500.00

• 9.

  Yue Xiong; Jing Wu

  Mechanisms of Oncometabolites in Epigenetics and Cancer

  7/1/2012 - 6/30/2013

  Sponsor: Samuel Waxman Cancer Research Foundation (SWCRF)

  Funding: $ 100,000.00

• 10.

  Kevin Robertson

  AIDS Clinical Trials Group Network

  6/1/2012 - 5/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 273,149.00

• 11.

  Kevin Robertson; Julie Nelson

  AIDS Clinical Trials Group Network

  6/1/2012 - 5/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 87,787.00

• 12.

  Timothy Gershon

  Aerobic glycolysis regulates apoptosis in neurogenesis and medulloblastoma

  4/1/2012 - 3/31/2016

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 174,921.00

• 13.

  Timothy Gershon

  Aerobic glycolysis regulates apoptosis in neurogenesis and medulloblastoma

  4/1/2012 - 3/31/2016

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 176,618.00

• 14.

  C.J. Malanga

  Mechanisms of Alcohol Reward in a Humanized OPRM1 Mouse Model

  4/1/2012 - 3/31/2017

  Sponsor: NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  Funding: $ 31,727.00

• 15.

  C.J. Malanga

  Mechanisms of Alcohol Reward in a Humanized OPRM1 Mouse Model

  4/1/2012 - 3/31/2017

  Sponsor: NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  Funding: $ 31,727.00

• 16.

  David Huang; Aaron Abate'; Natalie Aucutt-Walter; Sierra Marino; Matthew Smith; Susan Wilson; Anne Beckwith

  ASBI 801 A Multicenter Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Obtained Within 24 Hours of a Nonhemorrhagic Ischemic Stroke.

  3/9/2012 - 3/8/2015

  Sponsor: Industry Sponsor

  Funding: $ 2,500.00

• 17.

  Yue Xiong; Derek Chiang; Jing Wu

  Mechanisms of Metabolic Gene Mutations in Cancer

  3/1/2012 - 2/28/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 307,100.00

• 18.

  James Evans; Jonathan Berg; Gail Henderson; Karen Weck-Taylor; Kirk Wilhelmsen; Arthur Aylsworth; Noel Brewer; Muge Calikoglu; Giselle Corbie-Smith; Jason Fine; Bob Greenwood; Brian Jensen; Eric Juengst; Feng-Chang Lin; Piotr Mieczkowski; Cynthia Powell; Christine Rini; Myra Roche; Debra Skinner; Patrick Sullivan

  NC GENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

  12/5/2011 - 11/30/2015

  Sponsor: NIH National Human Genome Research Institute (NHGRI)

  Funding: $ 1,587,168.00

• 19.

  William Snider

  ERK/MAPK regulation of cortical inhibitory interneurons

  9/30/2011 - 8/31/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 80,039.00

• 20.

  William Snider

  ERK/MAPK regulation of cortical inhibitory interneurons

  9/30/2011 - 8/31/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 6,955.00

• 21.

  William Snider; Jason Newbern

  ERK/MAPK regulation of cortical inhibitory interneurons

  9/30/2011 - 8/31/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 86,994.00

• 22.

  John Mann

  THERAPEUTIC MASSAGE FOR MANAGEMENT OF PAIN AND DISABILITY IN TENSION TYPE HEADACHE

  9/30/2011 - 9/29/2012

  Sponsor: University of Colorado

  Funding: $ 5,000.00

• 23.

  Dinggang Shen; Yong Fan; John Gilmore; Daniel Kaufer; Weili Lin; J. Keith Smith; Hongtu Zhu

  Fast, Robust Analysis of Large Population Data

  9/1/2011 - 8/31/2015

  Sponsor: NIH National Institute of Biomedical Imaging and Bioengineering

  Funding: $ 333,000.00

• 24.

  Dinggang Shen; John Gilmore; Daniel Kaufer; Weili Lin; J Smith; Hongtu Zhu

  Fast, Robust Analysis of Large Population Data

  9/1/2011 - 8/31/2015

  Sponsor: NIH National Institute of Biomedical Imaging and Bioengineering

  Funding: $ 333,000.00

• 25.

  Caterina Gallippi; Daniel Bogan; Janet Bogan; James Howard; Joe Kornegay; Hongtu Zhu

  DP ARF Ultrasound for Monitoring Muscle Degeneration in Duchenne Muscular Dystrophy

  9/1/2011 - 8/31/2016

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 413,756.00

• 26.

  Caterina Gallippi; James Howard; Hongtu Zhu

  DP ARF Ultrasound for Monitoring Muscle Degeneration in Duchenne Muscular Dystrophy

  9/1/2011 - 8/31/2016

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 437,786.00

• 27.

  Ronald Swanstrom; Joseph Eron; Angela Kashuba; Kevin Robertson; Prema Menezes

  HIV Tropism, Persistence, Inflammation and Neurocognition in Therapy Initiation

  8/22/2011 - 5/31/2016

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 921,118.00

• 28.

  Ronald Swanstrom; Joseph Eron; Angela Kashuba; Prema Menezes; Kevin Robertson

  HIV Tropism, Persistence, Inflammation and Neurocognition in Therapy Initiation

  8/22/2011 - 5/31/2016

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 903,410.00

• 29.

  Jing Wu

  MPC-6827-021.03 A Phase 2 study of verubulin (MPC-6827) with radiation therapy and temozolomide in subjects newly diagnosed with Glioblastoma multiforme

  8/16/2011 - 8/15/2014

  Sponsor: Industry Sponsor

  Funding: $ 21,811.00

• 30.

  Timothy Gershon

  Jak-Stat signaling: a driving force and novel target for medulloblastoma

  7/1/2011 - 6/30/2014

  Sponsor: St Baldricks Foundation

  Funding: $ 330,000.00

• 31.

  Yue Xiong; Jing Wu

  MECHANISMS OF ONCOMETABOLITES IN EPIGENETICS AND CANCER

  7/1/2011 - 6/30/2012

  Sponsor: Samuel Waxman Cancer Research Foundation (SWCRF)

  Funding: $ 100,000.00

• 32.

  Silva Markovic-Plese; Manisha Chopra

  Biomarkers of Interferon beta 1a's immunoregulatory effects targerting Th17 cell-mediated response in patients with relapsing remitting multiple sclerosis.

  6/29/2011 - 6/28/2014

  Sponsor: Industry Sponsor

  Funding: $ 43,285.00

• 33.

  Silva Markovic-Plese; Manisha Chopra

  Biomarkers of Interferon beta 1a's immunoregulatory effects targerting Th17 cell-mediated response in patients with relapsing remitting multiple sclerosis.

  6/29/2011 - 6/28/2014

  Sponsor: Industry Sponsor

  Funding: $ 43,285.00

• 34.

  Silva Markovic-Plese; Manisha Chopra

  Biomarkers of Interferon beta 1a's immunoregulatory effects targerting Th17 cell-mediated response in patients with relapsing remitting multiple sclerosis.

  6/29/2011 - 6/28/2014

  Sponsor: Industry Sponsor

  Funding: $ 43,285.00

• 35.

  David Huang

  A9541004 A Phase 2 Multicenter, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of PF-03049423 in Subjects with Ischemic Stroke

  5/25/2011 - 5/24/2014

  Sponsor: Industry Sponsor

  Funding: $ 4,000.00

• 36.

  David Huang

  A9541004 A Phase 2 Multicenter, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of PF-03049423 in Subjects with Ischemic Stroke

  5/25/2011 - 5/24/2014

  Sponsor: Industry Sponsor

  Funding: $ 2,280.00

• 37.

  David Huang

  A9541004 A Phase 2 Multicenter, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of PF-03049423 in Subjects with Ischemic Stroke

  5/25/2011 - 5/24/2014

  Sponsor: Industry Sponsor

  Funding: $ 500.00

• 38.

  David Huang

  A9541004 A Phase 2 Multicenter, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of PF-03049423 in Subjects with Ischemic Stroke

  5/25/2011 - 5/24/2014

  Sponsor: Industry Sponsor

  Funding: $ 74,268.00

• 39.

  James Howard; Manisha Chopra

  CY4023 A Phase II, Double-Blind, Randomized, Three Way Crossover, PLacebo-Controlled, Pharmacydynamics study of CK-2017357 in patients with Generalized Myasthenia Gravis on Standard Therapy.

  4/30/2011 - 4/1/2013

  Sponsor: Industry Sponsor

  Funding: $ 4,780.00

• 40.

  James Howard; Manisha Chopra

  CY4023 A Phase II, Double-Blind, Randomized, Three Way Crossover, PLacebo-Controlled, Pharmacydynamics study of CK-2017357 in patients with Generalized Myasthenia Gravis on Standard Therapy.

  4/30/2011 - 4/1/2013

  Sponsor: Industry Sponsor

  Funding: $ 13,351.00

• 41.

  James Howard; Manisha Chopra

  CY4023 A Phase II, Double-Blind, Randomized, Three Way Crossover, PLacebo-Controlled, Pharmacydynamics study of CK-2017357 in patients with Generalized Myasthenia Gravis on Standard Therapy.

  4/30/2011 - 4/1/2013

  Sponsor: Industry Sponsor

  Funding: $ 501.00

• 42.

  James Howard; Manisha Chopra

  CY4023 A Phase II, Double-Blind, Randomized, Three Way Crossover, PLacebo-Controlled, Pharmacydynamics study of CK-2017357 in patients with Generalized Myasthenia Gravis on Standard Therapy.

  4/30/2011 - 4/1/2013

  Sponsor: Industry Sponsor

  Funding: $ 15,693.00

• 43.

  Silva Markovic-Plese; Manisha Chopra

  ICAMMS1011 T-Regulatory Cell Mediated reconstitutionof Immune Tolerance in Alemtuzumab-Induced Lymphopenia

  4/29/2011 - 4/28/2014

  Sponsor: Industry Sponsor

  Funding: $ 4,000.00

• 44.

  Silva Markovic-Plese; Manisha Chopra

  ICAMMS1011 T-Regulatory Cell Mediated reconstitutionof Immune Tolerance in Alemtuzumab-Induced Lymphopenia

  4/29/2011 - 4/28/2014

  Sponsor: Industry Sponsor

  Funding: $ 127,272.00

• 45.

  James Howard; Manisha Chopra

  MGO112479 A Randomized, PLacebo Controlled, Double-Blind STudy to Evaluate the Safety, Tolerability and Pharmacodynamics of multiple doses of Otelixizumab in patients with Myathenia Gravis

  1/20/2011 - 1/19/2017

  Sponsor: Industry Sponsor

  Funding: $ 8,960.00

• 46.

  Silva Markovic-Plese; Manisha Chopra

  CAMMS03409 An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme Sponsored Studies of Alemtuzumab.

  12/17/2010 - 12/16/2014

  Sponsor: Industry Sponsor

  Funding: $ 4,000.00

• 47.

  Silva Markovic-Plese; Manisha Chopra

  CAMMS03409 An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme Sponsored Studies of Alemtuzumab.

  12/17/2010 - 12/16/2014

  Sponsor: Industry Sponsor

  Funding: $ 1,255.00

• 48.

  Silva Markovic-Plese; Manisha Chopra

  CAMMS03409 An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme Sponsored Studies of Alemtuzumab.

  12/17/2010 - 12/16/2014

  Sponsor: Industry Sponsor

  Funding: $ 4,918.00

• 49.

  Silva Markovic-Plese; Manisha Chopra

  CAMMS03409 An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme Sponsored Studies of Alemtuzumab.

  12/17/2010 - 12/16/2014

  Sponsor: Industry Sponsor

  Funding: $ 10,642.00

• 50.

  Silva Markovic-Plese; Manisha Chopra

  CAMMS03409 An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme Sponsored Studies of Alemtuzumab.

  12/17/2010 - 12/16/2014

  Sponsor: Industry Sponsor

  Funding: $ 8,785.00

• 51.

  Silva Markovic-Plese; Manisha Chopra

  CAMMS03409 An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme Sponsored Studies of Alemtuzumab.

  12/17/2010 - 12/16/2014

  Sponsor: Industry Sponsor

  Funding: $ 15,286.00

• 52.

  Silva Markovic-Plese; Manisha Chopra

  CAMMS03409 An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme Sponsored Studies of Alemtuzumab.

  12/17/2010 - 12/16/2014

  Sponsor: Industry Sponsor

  Funding: $ 23,308.00

• 53.

  Silva Markovic-Plese; Manisha Chopra

  CAMMS03409 An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme Sponsored Studies of Alemtuzumab.

  12/17/2010 - 12/16/2014

  Sponsor: Industry Sponsor

  Funding: $ 8,425.00

• 54.

  Kevin Robertson; Ronald Swanstrom

  The Neuropathobiology of Primary HIV-1 Infection

  11/26/2010 - 1/31/2014

  Sponsor: Yale University

  Funding: $ 82,283.00

• 55.

  Kevin Robertson; Ronald Swanstrom

  The Neuropathobiology of Primary HIV-1 Infection

  11/26/2010 - 1/31/2014

  Sponsor: Yale University

  Funding: $ 86,264.00

• 56.

  Kevin Robertson; Ronald Swanstrom

  The Neuropathobiology of Primary HIV-1 Infection

  11/26/2010 - 1/31/2014

  Sponsor: Yale University

  Funding: $ 66,375.00

• 57.

  Daniel Kaufer; Brandi McCullough; Carla Gene Rapp

  AL-108-231 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

  11/8/2010 - 11/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 2,700.00

• 58.

  Daniel Kaufer; Brandi McCullough; Carla Gene Rapp

  AL-108-231 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

  11/8/2010 - 11/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 11,816.00

• 59.

  Daniel Kaufer; Glenn Barnes; Mary Tiger

  AL-108-231 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

  11/8/2010 - 11/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 22,753.00

• 60.

  Daniel Kaufer; Brandi McCullough; Carla Gene Rapp

  AL-108-231 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

  11/8/2010 - 11/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 2,667.00

• 61.

  Daniel Kaufer; Brandi McCullough; Carla Gene Rapp

  AL-108-231 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

  11/8/2010 - 11/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 8,609.00

• 62.

  Daniel Kaufer; Brandi McCullough; Carla Gene Rapp

  AL-108-231 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

  11/8/2010 - 11/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 7,302.00

• 63.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,000.00

• 64.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 210.00

• 65.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 840.00

• 66.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 2,940.00

• 67.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 210.00

• 68.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 840.00

• 69.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 420.00

• 70.

  Silva Markovic-Plese

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 65.00

• 71.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 65.00

• 72.

  Silva Markovic-Plese; Dianne Glover; Kimberly Kennedy

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 260.00

• 73.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 130.00

• 74.

  Silva Markovic-Plese; Manisha Chopra

  101JC402 JCV Antibody Program in patients with Relapsing Multiple Sclerosis receiving or considering treatment with Tysabri: STRATIFY-2

  10/11/2010 - 10/10/2013

  Sponsor: Industry Sponsor

  Funding: $ 359.00

• 75.

  John Mann

  THERAPEUTIC MASSAGE FOR MANAGEMENT OF PAIN AND DISABILITY IN TENSION TYPE HEADACHE

  9/30/2010 - 9/29/2011

  Sponsor: University of Colorado

  Funding: $ 5,000.00

• 76.

  Sutapa Ford; Susan Gaylord; Kevin Guskiewicz; John Mann; Chirayath Suchindran; Rebecca Coble

  PT090084 Post Traumatic Headache and Psychological Health Mindfulness Training

  9/27/2010 - 9/26/2013

  Sponsor: Army Research Office (ARO)

  Funding: $ 936,710.00

• 77.

  Souvik Sen; Hongyu An; Joseph Eron; Weili Lin; William Powers; Kevin Robertson; Hongtu Zhu

  Effect of HIV infection and antiretroviral therapy on cerebral autoregulation

  9/17/2010 - 6/30/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 366,986.00

• 78.

  Souvik Sen; Hongyu An; Weili Lin; Prema Menezes; William Powers; Kevin Robertson; Hongtu Zhu; Jonathan Oakes

  Effect of HIV infection and antiretroviral therapy on cerebral autoregulation

  9/17/2010 - 6/30/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 366,986.00

• 79.

  Souvik Sen; Hongyu An; Weili Lin; Prema Menezes; William Powers; Kevin Robertson; Hongtu Zhu; Jonathan Oakes

  Effect of HIV infection and antiretroviral therapy on cerebral autoregulation

  9/17/2010 - 6/30/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 359,646.00

• 80.

  Natalie Aucutt-Walter; David Huang; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 3,000.00

• 81.

  Natalie Aucutt-Walter; David Huang; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 3,900.00

• 82.

  Natalie Aucutt-Walter; David Huang; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,950.00

• 83.

  Natalie Aucutt-Walter; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,950.00

• 84.

  Natalie Aucutt-Walter; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 3,900.00

• 85.

  Natalie Aucutt-Walter; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 3,900.00

• 86.

  Natalie Aucutt-Walter; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 7,800.00

• 87.

  Natalie Aucutt-Walter; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 5,850.00

• 88.

  Natalie Aucutt-Walter; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,950.00

• 89.

  Natalie Aucutt-Walter; David Huang; Dedrick Jordan; Michael Wang; Susan Wilson; Aaron Abate'; Anne Beckwith; Sierra Marino; Roxanne Poole

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 9,750.00

• 90.

  Natalie Aucutt-Walter; David Huang; Dedrick Jordan; Michael Wang; Susan Wilson; Aaron Abate'; Anne Beckwith; Sierra Marino

  Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

  9/1/2010 - 9/28/2013

  Sponsor: Industry Sponsor

  Funding: $ 5,850.00

• 91.

  Ana Felix; Patricia Gregory

  Lower Ischemic Future Event Risk (LIFER) Study

  8/15/2010 - 8/14/2011

  Sponsor: Pfizer Health Foundation

  Funding: $ 189,778.00

• 92.

  Silva Markovic-Plese

  Alemtuzumab-induced Prolonged Suppression of the Autoimmune Response is initiate

  7/19/2010 - 7/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 93.

  Silva Markovic-Plese

  Alemtuzumab-induced Prolonged Suppression of the Autoimmune Response is initiate

  7/19/2010 - 7/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 36,671.00

• 94.

  Silva Markovic-Plese

  Alemtuzumab-induced Prolonged Suppression of the Autoimmune Response is initiate

  7/19/2010 - 7/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 12,918.00

• 95.

  Silva Markovic-Plese

  Alemtuzumab-induced Prolonged Suppression of the Autoimmune Response is initiate

  7/19/2010 - 7/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 273,957.00

• 96.

  Silva Markovic-Plese

  Th17 Phenotype of Auto-reactive T-cells in Patients with Relapsing Remitting Mul

  7/1/2010 - 6/30/2013

  Sponsor: Dana Foundation

  Funding: $ 200,000.00

• 97.

  David Huang; Susan Wilson

  NEST 3

  4/27/2010 - 4/26/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,875.00

• 98.

  David Huang; Susan Wilson

  NEST 3

  4/27/2010 - 4/26/2013

  Sponsor: Industry Sponsor

  Funding: $ 4,125.00

• 99.

  David Huang; Susan Wilson

  NEST 3

  4/27/2010 - 4/26/2013

  Sponsor: Industry Sponsor

  Funding: $ 161.00

• 100.

  David Huang; Susan Wilson

  NEST 3

  4/27/2010 - 4/26/2013

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 101.

  David Huang; Susan Wilson

  NEST 3

  4/27/2010 - 4/26/2013

  Sponsor: Industry Sponsor

  Funding: $ 100.00

• 102.

  David Huang; Susan Wilson

  NEST 3

  4/27/2010 - 4/26/2013

  Sponsor: Industry Sponsor

  Funding: $ 5,038.00

• 103.

  David Huang

  NEST 3

  4/27/2010 - 4/26/2013

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 104.

  Silva Markovic-Plese

  IFNb-1a inhibits Th17-mediated Autoimmune Responses in Relapsing remitting Multiple Sclerosis.

  4/1/2010 - 3/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 66,328.00

• 105.

  Silva Markovic-Plese

  IFNb-1a inhibits Th17-mediated Autoimmune Responses in Relapsing remitting Multiple Sclerosis.

  4/1/2010 - 3/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 66,328.00

• 106.

  Silva Markovic-Plese

  IFNb-1a inhibits Th17-mediated Autoimmune Responses in Relapsing remitting Multiple Sclerosis.

  4/1/2010 - 3/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 33,164.00

• 107.

  Silva Markovic-Plese

  IFNb-1a inhibits Th17-mediated Autoimmune Responses in Relapsing remitting Multiple Sclerosis.

  4/1/2010 - 3/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 33,164.00

• 108.

  C.J. Malanga

  Effects of Acute and Chronic Alcohol on Brain Reward in Mice

  2/1/2010 - 1/31/2014

  Sponsor: NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  Funding: $ 325,063.00

• 109.

  C.J. Malanga

  Effects of Acute and Chronic Alcohol on Brain Reward in Mice

  2/1/2010 - 1/31/2014

  Sponsor: NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  Funding: $ 303,096.00

• 110.

  C.J. Malanga

  Effects of Acute and Chronic Alcohol on Brain Reward in Mice

  2/1/2010 - 1/31/2014

  Sponsor: NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  Funding: $ 20,610.00

• 111.

  C.J. Malanga

  Effects of Acute and Chronic Alcohol on Brain Reward in Mice

  2/1/2010 - 1/31/2014

  Sponsor: NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  Funding: $ 336,806.00

• 112.

  C.J. Malanga

  Effects of Acute and Chronic Alcohol on Brain Reward in Mice

  2/1/2010 - 1/31/2014

  Sponsor: NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  Funding: $ 303,031.00

• 113.

  Elizabeth Geller; James Howard

  Pudendal Nerve Function as a Predictor of Female Sexual Function with Sacral Neu

  1/1/2010 - 3/30/2011

  Sponsor: American Urogynecologic Society (AUGS) Foundation

  Funding: $ 13,000.00

• 114.

  Silva Markovic-Plese; Manisha Chopra

  ITN035AI A Phase II Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to evaluate the safety and efficacy of Abatacept in Adults with Relapsing Remitting Multiple Sclerosis

  1/1/2010 - 4/30/2014

  Sponsor: University of California at San Francisco (UCSF)

  Funding: $ 28,003.00

• 115.

  Silva Markovic-Plese; Manisha Chopra

  ITN035AI A Phase II Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to evaluate the safety and efficacy of Abatacept in Adults with Relapsing Remitting Multiple Sclerosis

  1/1/2010 - 4/30/2014

  Sponsor: University of California at San Francisco (UCSF)

  Funding: $ 46,414.00

• 116.

  Silva Markovic-Plese; Manisha Chopra

  ITN035AI A Phase II Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to evaluate the safety and efficacy of Abatacept in Adults with Relapsing Remitting Multiple Sclerosis

  1/1/2010 - 4/30/2014

  Sponsor: University of California at San Francisco (UCSF)

  Funding: $ 18,724.00

• 117.

  James Howard; Manisha Chopra

  MGO113510 Investigation of the ability of Otelixizumab to inhibit in vitro ant

  12/21/2009 - 12/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,738.00

• 118.

  James Howard; Manisha Chopra

  MGO113510 Investigation of the ability of Otelixizumab to inhibit in vitro ant

  12/21/2009 - 12/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 9,102.00

• 119.

  James Howard; Manisha Chopra

  MGO113510 Investigation of the ability of Otelixizumab to inhibit in vitro ant

  12/21/2009 - 12/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,738.00

• 120.

  James Howard

  Genome Wide Association study in Myasthenia Gravis

  11/1/2009 - 10/31/2010

  Sponsor: Johns Hopkins University

  Funding: $ 8,350.00

• 121.

  James Howard; Roy Orlando; Constantina Gallins

  Genome Wide Association study in Myasthenia Gravis

  11/1/2009 - 10/31/2010

  Sponsor: Johns Hopkins University

  Funding: $ 1,837.00

• 122.

  James Howard

  Genome Wide Association study in Myasthenia Gravis

  11/1/2009 - 10/31/2010

  Sponsor: Johns Hopkins University

  Funding: $ 3,340.00

• 123.

  James Howard

  Genome Wide Association study in Myasthenia Gravis

  11/1/2009 - 10/31/2010

  Sponsor: Johns Hopkins University

  Funding: $ 1,503.00

• 124.

  Franck Polleux; William Snider

  Fellow:Meghan Morgan Smith-Exploring the Role of TAK1 in Neuronal Polarization

  9/30/2009 - 9/29/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 30,091.00

• 125.

  John Mann

  THERAPEUTIC MASSAGE FOR MANAGEMENT OF PAIN AND DISABILITY IN TENSION-TYPE HEADAC

  9/30/2009 - 9/29/2010

  Sponsor: University of Colorado

  Funding: $ 5,000.00

• 126.

  Rick Meeker

  Quantifying Cognitive-Motor Decline In FIV-Infected Cats

  9/30/2009 - 7/31/2012

  Sponsor: North Carolina State University (NCSU)

  Funding: $ 19,200.00

• 127.

  Kevin Robertson

  CNS Immune/Inflammatory Biomarkers in HIV Controllers

  9/25/2009 - 8/31/2011

  Sponsor: University of California at Davis (UCD)

  Funding: $ 10,748.00

• 128.

  Kevin Robertson

  CNS Immune/Inflammatory Biomarkers in HIV Controllers

  9/25/2009 - 8/31/2011

  Sponsor: University of California at Davis (UCD)

  Funding: $ 10,748.00

• 129.

  Timothy Gershon

  Interaction of retinoic acid and mTOR signaling pathways in cerebellar progenito

  9/1/2009 - 8/31/2010

  Sponsor: Memorial Sloan Kettering Institute for Cancer Center

  Funding: $ 65,000.00

• 130.

  Caterina Gallippi; David Huang; Matt Mauro; Timothy Nichols; Cam Patterson; Hongtu Zhu

  ARFI ultrasound for noninvasive, Diagnostic atherosclerosis imaging

  8/1/2009 - 6/30/2014

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 362,876.00

• 131.

  Steve Marshall; Carol Runyan; Hongyu An; Shrikant Bangdiwala; Troy Blackburn; Susan Blalock; James Bowling; Carri Casteel; Mimi Chapman; Christine Durrance; Susan Ennett; Vangie Foshee; Kevin Guskiewicz; Margaret Jablonski; Daniel Kaufer; Beth Moracco; Darin Padua; Krista Perreira; Kimberly Rauscher; J. Keith Smith; Karla Thompson; Andres Villaveces

  UNC Injury Prevention Research Center

  8/1/2009 - 7/31/2014

  Sponsor: National Center for Injury Prevention and Control (NCIPC)

  Funding: $ 974,403.00

• 132.

  Benjamin Huang; David Huang; Matthew Ostrander; Souvik Sen; Susan Wilson; Shannon Boughton

  DGD-44-048 Evaluation Of Dotarem-Enhanced MRA Compared To Time-Of-Flight MRA

  7/20/2009 - 7/19/2012

  Sponsor: Industry Sponsor

  Funding: $ 24,468.00

• 133.

  Benjamin Huang; David Huang; Matthew Ostrander; Souvik Sen; Susan Wilson; Shannon Boughton

  DGD-44-048 Evaluation Of Dotarem-Enhanced MRA Compared To Time-Of-Flight MRA

  7/20/2009 - 7/19/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 134.

  Benjamin Huang; David Huang; Matthew Ostrander; Souvik Sen; Susan Wilson; Shannon Boughton

  DGD-44-048 Evaluation Of Dotarem-Enhanced MRA Compared To Time-Of-Flight MRA

  7/20/2009 - 7/19/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,576.00

• 135.

  Benjamin Huang; David Huang; Matthew Ostrander; Souvik Sen; Susan Wilson; Shannon Boughton

  DGD-44-048 Evaluation Of Dotarem-Enhanced MRA Compared To Time-Of-Flight MRA

  7/20/2009 - 7/19/2012

  Sponsor: Industry Sponsor

  Funding: $ 666.00

• 136.

  Rick Meeker; Youmei Xie

  Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction

  7/1/2009 - 3/31/2014

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 351,451.00

• 137.

  Rick Meeker; Youmei Xie

  Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction

  7/1/2009 - 3/31/2014

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 333,000.00

• 138.

  Rick Meeker; Youmei Xie

  Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction

  7/1/2009 - 3/31/2014

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 299,700.00

• 139.

  Rick Meeker; Youmei Xie

  Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction

  7/1/2009 - 3/31/2014

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 29,970.00

• 140.

  Rick Meeker; Youmei Xie

  Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction

  7/1/2009 - 3/31/2014

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 329,670.00

• 141.

  Rick Meeker; Youmei Xie

  Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction

  7/1/2009 - 3/31/2014

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 296,703.00

• 142.

  Susan Gaylord; Cheryl Giscombe; John Buse; John Mann; Anne Skelly; Kim Faurot

  A Mindfulness-based Intervention to Reduce Diabetes Risk in Prediabetic Afr-Amer

  7/1/2009 - 6/30/2013

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 184,375.00

• 143.

  Susan Gaylord; Cheryl Giscombe; Shrikant Bangdiwala; John Buse; John Mann; Anne Skelly; Rebecca Coble

  A Mindfulness-based Intervention to Reduce Diabetes Risk in Prediabetic Afr-Amer

  7/1/2009 - 6/30/2013

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 219,780.00

• 144.

  Susan Gaylord; Cheryl Giscombe; John Buse; John Mann

  A Mindfulness-based Intervention to Reduce Diabetes Risk in Prediabetic Afr-Amer

  7/1/2009 - 6/30/2013

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 181,318.00

• 145.

  Silva Markovic-Plese; Jp Jin

  IMMUNOMODULATORY EFFECTS OF STATINS

  7/1/2009 - 6/30/2012

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 363,887.00

• 146.

  Bradley Vaughn

  112563 SIT Test For Early Detection of RLS Augmentation - Proof of Concept

  6/1/2009 - 5/31/2011

  Sponsor: Johns Hopkins University

  Funding: $ 6,570.00

• 147.

  Bradley Vaughn

  112563 SIT Test For Early Detection of RLS Augmentation - Proof of Concept

  6/1/2009 - 5/31/2011

  Sponsor: Johns Hopkins University

  Funding: $ 2,800.00

• 148.

  Kevin Robertson

  International Network for Strategic Iniatives in Global HIV Trials:Strategic

  6/1/2009 - 5/31/2013

  Sponsor: University of Minnesota

  Funding: $ 17,051.00

• 149.

  Kevin Robertson

  International Network for Strategic Iniatives in Global HIV Trials:Strategic

  6/1/2009 - 5/31/2013

  Sponsor: University of Minnesota

  Funding: $ 17,051.00

• 150.

  Kevin Robertson

  International Network for Strategic Iniatives in Global HIV Trials:Strategic

  6/1/2009 - 5/31/2013

  Sponsor: University of Minnesota

  Funding: $ 16,895.00

• 151.

  Kevin Robertson

  International Network for Strategic Iniatives in Global HIV Trials:Strategic

  6/1/2009 - 5/31/2013

  Sponsor: University of Minnesota

  Funding: $ 17,394.00

• 152.

  John Mann; Susan Gaylord; Beth Macintosh; Chirayath Suchindran; Kim Faurot

  Exploratory Analgesic Dietary Intervention for Chronic Daily Headache

  5/1/2009 - 4/30/2012

  Sponsor: Mayday Fund

  Funding: $ 239,985.00

• 153.

  Susan Wilson

  CLP 1953.A Penumbra Imaging Collaborative Study (PICS): A Multicenter Trial

  4/15/2009 - 4/11/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,000.00

• 154.

  William Snider

  The In Vivo Role of ERK1/2 Signaling in Peripheral Nervous System Development

  4/1/2009 - 3/31/2011

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 49,646.00

• 155.

  William Snider

  The In Vivo Role of ERK1/2 Signaling in Peripheral Nervous System Development

  4/1/2009 - 3/31/2011

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 408.00

• 156.

  William Snider

  The In Vivo Role of ERK 1/2 Signaling in Peripheral Nervous System Development

  4/1/2009 - 3/31/2011

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 52,154.00

• 157.

  Hongtu Zhu; Yong Fan; Daniel Kaufer; Dinggang Shen

  Longitudinal Analysis of Biomedical Imaging Data

  3/1/2009 - 2/28/2012

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 183,419.00

• 158.

  Hongtu Zhu; Daniel Kaufer; Dinggang Shen

  Longitudinal Analysis of Biomedical Imaging Data

  3/1/2009 - 2/28/2012

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 150,341.00

• 159.

  David Huang; Roxanne Poole; Susan Wilson

  MP-124-A01 A Phase I, Double-Blind, Placebo-Controlled, Ascending Dose, Clini

  2/19/2009 - 2/18/2012

  Sponsor: Industry Sponsor

  Funding: $ 34,581.00

• 160.

  Sharon Williams; Ana Felix; Patricia Gregory

  Stroke Telemedicine Access Recovery (STAR) Project

  1/1/2009 - 6/30/2012

  Sponsor: Duke Endowment

  Funding: $ 349,995.00

• 161.

  James Howard

  C08-001 A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-cent

  12/19/2008 - 12/18/2011

  Sponsor: Industry Sponsor

  Funding: $ 4,500.00

• 162.

  James Howard

  C08-001 A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-cent

  12/19/2008 - 12/18/2011

  Sponsor: Industry Sponsor

  Funding: $ 13,843.00

• 163.

  James Howard

  C08-001 A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-cent

  12/19/2008 - 12/18/2011

  Sponsor: Industry Sponsor

  Funding: $ 128.00

• 164.

  James Howard

  C08-001 A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-cent

  12/19/2008 - 12/18/2011

  Sponsor: Industry Sponsor

  Funding: $ 9,797.00

• 165.

  James Howard

  C08-001 A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-cent

  12/19/2008 - 12/18/2011

  Sponsor: Industry Sponsor

  Funding: $ 655.00

• 166.

  Silva Markovic-Plese; Danielle Speer; Xin Zhang; Liseanne Fedor-Hammonds

  Characterization of immunological reconstitution following Alemtuzumab therapy i

  11/18/2008 - 11/17/2011

  Sponsor: Industry Sponsor

  Funding: $ 47,760.00

• 167.

  Silva Markovic-Plese; Danielle Speer; Xin Zhang; Liseanne Fedor-Hammonds

  Characterization of immunological reconstitution following Alemtuzumab therapy i

  11/18/2008 - 11/17/2011

  Sponsor: Industry Sponsor

  Funding: $ 69,600.00

• 168.

  Silva Markovic-Plese; Danielle Speer; Xin Zhang; Liseanne Fedor-Hammonds

  Characterization of immunological reconstitution following Alemtuzumab therapy i

  11/18/2008 - 11/17/2011

  Sponsor: Industry Sponsor

  Funding: $ 69,600.00

• 169.

  Silva Markovic-Plese; Danielle Speer; Xin Zhang; Liseanne Fedor-Hammonds

  Characterization of immunological reconstitution following Alemtuzumab therapy i

  11/18/2008 - 11/17/2011

  Sponsor: Industry Sponsor

  Funding: $ 19,824.00

• 170.

  Phil Sloane; Mary Altpeter; Daniel Kaufer; Charlene Riedel-Leo

  Strengthening the Linkages between Primary Care Physicians and Aging Service Pro

  9/30/2008 - 12/31/2010

  Sponsor: DHHS Administration on Aging (AoA)

  Funding: $ 301,672.00

• 171.

  Kevin Robertson

  HIV Dementia and Sensory Neuropathy in Uganda

  9/8/2008 - 5/31/2012

  Sponsor: Johns Hopkins University

  Funding: $ 6,766.00

• 172.

  Kevin Robertson

  HIV Dementia and Sensory Neuropathy in Uganda

  9/8/2008 - 5/31/2012

  Sponsor: Johns Hopkins University

  Funding: $ 6,766.00

• 173.

  Richard Samulski; Edward Beecham; Joe Kornegay; William Powers; Xiao Xiao

  Senator Paul D. Welstone Muscular Dystrophy Cooperative Research Center ARRA

  9/5/2008 - 8/31/2013

  Sponsor: NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD)

  Funding: $ 1,491,322.00

• 174.

  Richard Samulski; Edward Beecham; Zheng (Jane) Fan; James Howard; Keith Kocis; Joe Kornegay; Joseph Muenzer; William Powers; Spencer Weig; Xiao Xiao

  Senator Paul D. Welstone Muscular Dystrophy Cooperative Research Center ARRA

  9/5/2008 - 8/31/2013

  Sponsor: NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD)

  Funding: $ 1,408,111.00

• 175.

  Richard Samulski; Edward Beecham; Zheng (Jane) Fan; Joe Kornegay; William Powers

  Senator Paul D. Welstone Muscular Dystrophy Cooperative Research Center ARRA

  9/5/2008 - 8/31/2013

  Sponsor: NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD)

  Funding: $ 52,295.00

• 176.

  Richard Samulski; Edward Beecham; Joe Kornegay; William Powers; Xiao Xiao; Manisha Chopra; Zheng (Jane) Fan; James Howard; Keith Kocis; Joseph Muenzer; Spencer Weig

  Senator Paul D. Welstone Muscular Dystrophy Cooperative Research Center ARRA

  9/5/2008 - 8/31/2013

  Sponsor: NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD)

  Funding: $ 1,404,947.00

• 177.

  Richard Samulski; Zheng (Jane) Fan; James Howard; Keith Kocis; Joe Kornegay; Juan Li; Joseph Muenzer; William Powers; Xiao Xiao

  Senator Paul D. Welstone Muscular Dystrophy Cooperative Research Center ARRA

  9/5/2008 - 8/31/2013

  Sponsor: NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD)

  Funding: $ 1,398,548.00

• 178.

  Richard Samulski; David Dismuke; Zheng (Jane) Fan; James Howard; Keith Kocis; Juan Li; William Powers; Chunping Qiao; Xiao Xiao; Manisha Chopra

  Senator Paul D. Welstone Muscular Dystrophy Cooperative Research Center ARRA

  9/5/2008 - 8/31/2013

  Sponsor: NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD)

  Funding: $ 1,391,658.00

• 179.

  Kevin Robertson; Ronald Swanstrom

  The Neuropathobiology of Primary HIV-1 Infection

  9/1/2008 - 7/31/2010

  Sponsor: University of California at San Francisco (UCSF)

  Funding: $ 90,689.00

• 180.

  Kevin Robertson; Ronald Swanstrom

  The Neuropathobiology of Primary HIV-1 Infection

  9/1/2008 - 7/31/2010

  Sponsor: University of California at San Francisco (UCSF)

  Funding: $ 92,052.00

• 181.

  Joey Johns; Margaret Burchinal; John Gilmore; Karen Grewen; Alan Hinderliter; Weili Lin; C.J. Malanga; Samantha Meltzer-Brody; Sheryl Moy; Martin Styner

  Neurobiological and Behavioral Consequences of Cocaine Use in Mother/Infant Dyad

  8/15/2008 - 5/31/2014

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 1,997,299.00

• 182.

  Joey Johns; Margaret Burchinal; John Gilmore; Karen Grewen; Alan Hinderliter; Weili Lin; C.J. Malanga; Samantha Meltzer-Brody; Sheryl Moy; Martin Styner

  Neurobiological and Behavioral Consequences of Cocaine Use in Mother/Infant Dyad

  8/15/2008 - 5/31/2014

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 58,588.00

• 183.

  Joey Johns; Margaret Burchinal; John Gilmore; Alan Hinderliter; Weili Lin; C.J. Malanga; Samantha Meltzer-Brody; Sheryl Moy; Martin Styner; Hong Yuan; Marisa DeBurkarte

  Neurobiological and Behavioral Consequences of Cocaine Use in Mother/Infant Dyad

  8/15/2008 - 5/31/2014

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 2,012,128.00

• 184.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  001-06-NAT Multi-center, Open-Label Study to Evaluate the Effects of Natalizu

  7/23/2008 - 6/30/2010

  Sponsor: Industry Sponsor

  Funding: $ 5,500.00

• 185.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  001-06-NAT Multi-center, Open-Label Study to Evaluate the Effects of Natalizu

  7/23/2008 - 6/30/2010

  Sponsor: Industry Sponsor

  Funding: $ 2,780.00

• 186.

  C.J. Malanga

  Neuropharmacology of Motivation and Reinforcement in Mouse Models of Autistic Sp

  7/1/2008 - 12/31/2011

  Sponsor: Autism Speaks

  Funding: $ 450,000.00

• 187.

  Weili Lin; Hongyu An; William Powers

  MR-Derived Cerebral Oxygen Metabolism as a Predictor of Infarction - SPOTRIAS

  7/1/2008 - 4/30/2013

  Sponsor: Washington University in Saint Louis

  Funding: $ 171,899.00

• 188.

  Weili Lin; Hongyu An; William Powers

  MR-Derived Cerebral Oxygen Metabolism as a Predictor of Infarction - SPOTRIAS

  7/1/2008 - 4/30/2013

  Sponsor: Washington University in Saint Louis

  Funding: $ 163,250.00

• 189.

  Weili Lin; Hongyu An; William Powers

  MR-Derived Cerebral Oxygen Metabolism as a Predictor of Infarction - SPOTRIAS

  7/1/2008 - 4/30/2013

  Sponsor: Washington University in Saint Louis

  Funding: $ 36,875.00

• 190.

  Weili Lin; Hongyu An; William Powers

  MR-Derived Cerebral Oxygen Metabolism as a Predictor of Infarction - SPOTRIAS

  7/1/2008 - 4/30/2013

  Sponsor: Washington University in Saint Louis

  Funding: $ 168,148.00

• 191.

  Weili Lin; Hongyu An; William Powers

  MR-Derived Cerebral Oxygen Metabolism as a Predictor of Infarction - SPOTRIAS

  7/1/2008 - 4/30/2013

  Sponsor: Washington University in Saint Louis

  Funding: $ 7,400.00

• 192.

  Weili Lin; Hongyu An; William Powers

  MR-Derived Cerebral Oxygen Metabolism as a Predictor of Infarction - SPOTRIAS

  7/1/2008 - 4/30/2013

  Sponsor: Washington University in Saint Louis

  Funding: $ 198,145.00

• 193.

  Weili Lin; Hongyu An; William Powers

  MR-Derived Cerebral Oxygen Metabolism as a Predictor of Infarction - SPOTRIAS

  7/1/2008 - 4/30/2013

  Sponsor: Washington University in Saint Louis

  Funding: $ 132,131.00

• 194.

  Weili Lin; Hongyu An; William Powers

  MR-Derived Cerebral Oxygen Metabolism as a Predictor of Infarction - SPOTRIAS

  7/1/2008 - 4/30/2013

  Sponsor: Washington University in Saint Louis

  Funding: $ 198,145.00

• 195.

  Daniel Kaufer; Charlene Riedel-Leo

  NAM-53 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo

  6/12/2008 - 6/11/2011

  Sponsor: Industry Sponsor

  Funding: $ 38,600.00

• 196.

  Daniel Kaufer; Charlene Riedel-Leo

  NAM-53 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo

  6/12/2008 - 6/11/2011

  Sponsor: Industry Sponsor

  Funding: $ 38,600.00

• 197.

  Daniel Kaufer; Charlene Riedel-Leo

  NAM-53 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo

  6/12/2008 - 6/11/2011

  Sponsor: Industry Sponsor

  Funding: $ 38,600.00

• 198.

  Daniel Kaufer; Charlene Riedel-Leo

  NAM-53 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo

  6/12/2008 - 6/11/2011

  Sponsor: Industry Sponsor

  Funding: $ 671.00

• 199.

  Daniel Kaufer

  NAM-53 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo

  6/12/2008 - 6/11/2011

  Sponsor: Industry Sponsor

  Funding: $ 43,952.00

• 200.

  Daniel Kaufer

  NAM-53 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo

  6/12/2008 - 6/11/2011

  Sponsor: Industry Sponsor

  Funding: $ 38,572.00

• 201.

  Phil Sloane; Daniel Kaufer; Sheryl Zimmerman

  Carolina Alzheimer's Network Proposal

  6/3/2008 - 12/31/2012

  Sponsor: Duke Endowment

  Funding: $ 540,491.00

• 202.

  David Couper; Silva Markovic-Plese; Javed Mostafa

  PEDIATRIC MS DATA COORDINATION AND ANALYSIS CENTER (DCAC)

  6/1/2008 - 5/31/2012

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 660,629.00

• 203.

  David Couper; Silva Markovic-Plese; Javed Mostafa

  PEDIATRIC MS DATA COORDINATION AND ANALYSIS CENTER (DCAC)

  6/1/2008 - 5/31/2012

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 1,820,143.00

• 204.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 8,600.00

• 205.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 2,162.00

• 206.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 25,124.00

• 207.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 13,879.00

• 208.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 29,457.00

• 209.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 1,043.00

• 210.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 43,162.00

• 211.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 24,586.00

• 212.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 2,476.00

• 213.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 43,565.00

• 214.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 16,760.00

• 215.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 12,984.00

• 216.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 9,850.00

• 217.

  Silva Markovic-Plese; Liseanne Fedor-Hammonds

  CAMMS32400507 A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing T

  5/5/2008 - 5/4/2011

  Sponsor: Industry Sponsor

  Funding: $ 19,135.00

• 218.

  Joe Kornegay; Caterina Gallippi; James Howard

  National Center for Canine Models of Duchene Muscular Dystrophy ARRA

  5/1/2008 - 4/30/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 95,000.00

• 219.

  Jenny Ting; Albert Baldwin; Manzoor Bhat; Silva Markovic-Plese; Glenn Matsushima

  Novel Immune Pathways in Multiple Sclerosis Pathogenesis and Therapy

  4/1/2008 - 3/31/2013

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 825,000.00

• 220.

  Danielle Speer; Silva Markovic-Plese

  The Motherhood Choice of Women with Multiple Sclerosis

  1/1/2008 - 12/31/2009

  Sponsor: International Organization of Multiple Sclerosis Nurses (IOMSN)

  Funding: $ 5,000.00

• 221.

  Kevin Robertson

  NEUROLOGIC AIDS RESEARCH CONSORTIUM

  1/1/2008 - 11/30/2011

  Sponsor: Washington University in Saint Louis

  Funding: $ 14,550.00

• 222.

  Kevin Robertson

  NEUROLOGIC AIDS RESEARCH CONSORTIUM

  1/1/2008 - 11/30/2011

  Sponsor: Washington University in Saint Louis

  Funding: $ 14,750.00

• 223.

  Kevin Robertson

  NEUROLOGIC AIDS RESEARCH CONSORTIUM

  1/1/2008 - 11/30/2011

  Sponsor: Washington University in Saint Louis

  Funding: $ 14,800.00

• 224.

  Kevin Robertson

  NEUROLOGIC AIDS RESEARCH CONSORTIUM

  1/1/2008 - 11/30/2011

  Sponsor: Washington University in Saint Louis

  Funding: $ 14,800.00

• 225.

  Bob Greenwood; Albert Hinn; Nora Schuette; Michael Tennison; Bradley Vaughn; Spencer Weig; Joan Olive

  A Historical-Controlled, Multicenter, Double-Blind, Randomized Trial to Assess t

  11/6/2007 - 11/4/2008

  Sponsor: Industry Sponsor

  Funding: $ 5,000.00

• 226.

  Silva Markovic-Plese

  Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic C

  8/6/2007 - 8/5/2010

  Sponsor: Industry Sponsor

  Funding: $ 39,635.00

• 227.

  Silva Markovic-Plese

  Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic C

  8/6/2007 - 8/5/2010

  Sponsor: Industry Sponsor

  Funding: $ 42,945.00

• 228.

  Silva Markovic-Plese

  Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic C

  8/6/2007 - 8/5/2010

  Sponsor: Industry Sponsor

  Funding: $ 42,946.00

• 229.

  Silva Markovic-Plese

  Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic C

  8/6/2007 - 8/5/2010

  Sponsor: Industry Sponsor

  Funding: $ 72,591.00

• 230.

  Bob Greenwood

  E2080-A001-302 An Open-Label Extension Study of Rufinamide Given as Adjunctive

  8/1/2007 - 7/31/2010

  Sponsor: Industry Sponsor

  Funding: $ 1,500.00

• 231.

  Bob Greenwood

  E2080-A001-302 An Open-Label Extension Study of Rufinamide Given as Adjunctive

  8/1/2007 - 7/31/2010

  Sponsor: Industry Sponsor

  Funding: $ 2,547.00

• 232.

  John Mann; Susan Gaylord

  UNC Research Fellowship in Complementary and Alternative Medicine

  7/1/2007 - 6/30/2017

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 120,983.00

• 233.

  Zheng (Jane) Fan

  Clinical Research Training Grant (Muscular Dystrophy Association)

  7/1/2007 - 6/30/2009

  Sponsor: Muscular Dystrophy Association (MDA)

  Funding: $ 177,479.00

• 234.

  John Mann; Susan Gaylord

  UNC Research Fellowship in Complementary and Alternative Medicine

  7/1/2007 - 6/30/2017

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 248,775.00

• 235.

  John Mann; Susan Gaylord

  UNC Research Fellowship in Complementary and Alternative Medicine

  7/1/2007 - 6/30/2017

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 377,999.00

• 236.

  John Mann; Susan Gaylord

  UNC Research Fellowship in Complementary and Alternative Medicine

  7/1/2007 - 6/30/2017

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 222,771.00

• 237.

  John Mann; Susan Gaylord

  UNC Research Fellowship in Complementary and Alternative Medicine

  7/1/2007 - 6/30/2017

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 90,763.00

• 238.

  John Mann; Susan Gaylord

  UNC Research Fellowship in Complementary and Alternative Medicine

  7/1/2007 - 6/30/2017

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 318,397.00

• 239.

  Ana Felix

  A Prospective Validation Study of the ABCD Score and Kaiser Criteria for Short-term Stroke Risk after Emergency Department Diagnosis of TIA

  7/1/2007 - 7/1/2012

  Sponsor: Charlotte Mecklenburg Hospital Authority Foundation

  Funding: $ 7,300.00

• 240.

  Sutapa Ford; Anne Calhoun; Alan Finkel; Kevin Kahn; John Mann

  110638 Exploring Markers for Suboptimal Headache Treatment Response and Functi

  6/4/2007 - 6/3/2010

  Sponsor: Industry Sponsor

  Funding: $ 25,000.00

• 241.

  Sutapa Ford; Anne Calhoun; Alan Finkel; Kevin Kahn; John Mann

  110638 Exploring Markers for Suboptimal Headache Treatment Response and Functi

  6/4/2007 - 6/3/2010

  Sponsor: Industry Sponsor

  Funding: $ 25,000.00

• 242.

  Sutapa Ford; Anne Calhoun; Alan Finkel; Kevin Kahn; John Mann

  110638 Exploring Markers for Suboptimal Headache Treatment Response and Functi

  6/4/2007 - 6/3/2010

  Sponsor: Industry Sponsor

  Funding: $ 33,824.00

• 243.

  Sutapa Ford; Anne Calhoun; Alan Finkel; Kevin Kahn; John Mann

  110638 Exploring Markers for Suboptimal Headache Treatment Response and Functi

  6/4/2007 - 6/3/2010

  Sponsor: Industry Sponsor

  Funding: $ 58,824.00

• 244.

  Sutapa Ford; Anne Calhoun; Alan Finkel; Kevin Kahn; John Mann

  110638 Exploring Markers for Suboptimal Headache Treatment Response and Functi

  6/4/2007 - 6/3/2010

  Sponsor: Industry Sponsor

  Funding: $ 28,706.00

• 245.

  Sutapa Ford; Anne Calhoun; Alan Finkel; Kevin Kahn; John Mann

  110638 Exploring Markers for Suboptimal Headache Treatment Response and Functi

  6/4/2007 - 6/3/2010

  Sponsor: Industry Sponsor

  Funding: $ 26,532.00

• 246.

  Silva Markovic-Plese

  Interferon Beta Induction of Tolerizing Effect in Dendritic Cells and Gamma Delt

  5/29/2007 - 5/28/2010

  Sponsor: Industry Sponsor

  Funding: $ 149,000.00

• 247.

  Silva Markovic-Plese

  Interferon Beta Induction of Tolerizing Effect in Dendritic Cells and Gamma Delt

  5/29/2007 - 5/28/2010

  Sponsor: Industry Sponsor

  Funding: $ 117,000.00

• 248.

  Silva Markovic-Plese

  Interferon Beta Induction of Tolerizing Effect in Dendritic Cells and Gamma Delt

  5/29/2007 - 5/28/2010

  Sponsor: Industry Sponsor

  Funding: $ 30,510.00

• 249.

  Silva Markovic-Plese

  Interferon Beta Induction of Tolerizing Effect in Dendritic Cells and Gamma Delt

  5/29/2007 - 5/28/2010

  Sponsor: Industry Sponsor

  Funding: $ 66,328.00

• 250.

  Richard Sutherland; Ana Felix; Peadar Noone; Patricia Robinson

  191622-082 A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOT

  5/8/2007 - 4/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 5,380.00

• 251.

  Richard Sutherland; Ana Felix; Peadar Noone; Patricia Robinson

  191622-082 A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOT

  5/8/2007 - 4/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 675.00

• 252.

  Richard Sutherland; Ana Felix; Peadar Noone; Patricia Robinson

  191622-082 A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOT

  5/8/2007 - 4/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 1,930.00

• 253.

  William Powers

  CAROTID OCCLUSION SURGERY STUDY

  5/1/2007 - 11/30/2007

  Sponsor: Washington State University

  Funding: $ 135,336.00

• 254.

  Hank Van Deventer; David Huang

  152-CL-201 Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate

  4/18/2007 - 4/17/2010

  Sponsor: Industry Sponsor

  Funding: $ 12,600.00

• 255.

  David Huang

  NeuroThera Effectiveness & Safety Trial - 2 (NEST-2) A double blind, randomized

  4/2/2007 - 4/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 7,000.00

• 256.

  David Huang

  NeuroThera Effectiveness & Safety Trial - 2 (NEST-2) A double blind, randomized

  4/2/2007 - 4/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 8,473.00

• 257.

  David Huang

  NeuroThera Effectiveness & Safety Trial - 2 (NEST-2) A double blind, randomized

  4/2/2007 - 4/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 17,983.00

• 258.

  David Huang

  NeuroThera Effectiveness & Safety Trial - 2 (NEST-2) A double blind, randomized

  4/2/2007 - 4/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 149.00

• 259.

  David Huang

  NeuroThera Effectiveness & Safety Trial - 2 (NEST-2) A double blind, randomized

  4/2/2007 - 4/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 105.00

• 260.

  David Huang

  NeuroThera Effectiveness & Safety Trial - 2 (NEST-2) A double blind, randomized

  4/2/2007 - 4/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 42,366.00

• 261.

  David Huang

  NeuroThera Effectiveness & Safety Trial - 2 (NEST-2) A double blind, randomized

  4/2/2007 - 4/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 7,625.00

• 262.

  David Huang

  NeuroThera Effectiveness & Safety Trial - 2 (NEST-2) A double blind, randomized

  4/2/2007 - 4/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 13,557.00

• 263.

  David Huang

  NeuroThera Effectiveness & Safety Trial - 2 (NEST-2) A double blind, randomized

  4/2/2007 - 4/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 4,125.00

• 264.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 13,004.00

• 265.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 500.00

• 266.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 21,940.00

• 267.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 4,975.00

• 268.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 12,935.00

• 269.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 3,408.00

• 270.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 8,268.00

• 271.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 2,783.00

• 272.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 3,832.00

• 273.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 3,303.00

• 274.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 6,015.00

• 275.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 234.00

• 276.

  Bob Greenwood; O'Neill D'Cruz; Albert Hinn; Bradley Vaughn; Spencer Weig

  E2080-A001-301 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Ru

  3/27/2007 - 3/26/2010

  Sponsor: Pharmaceutical Research Associates (PRA)

  Funding: $ 2,281.00

• 277.

  Rick Meeker

  Neuroprotective and anti-inflammatory actions of novel growth factor mimetics

  1/1/2007 - 12/31/2009

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 190,890.00

• 278.

  Rick Meeker; Frank Longo

  Neuroprotective and anti-inflammatory actions of novel growth factor mimetics

  1/1/2007 - 12/31/2009

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 21,210.00

• 279.

  Rick Meeker

  Neuroprotective and anti-inflammatory actions of novel growth factor mimetics

  1/1/2007 - 12/31/2009

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 131,400.00

• 280.

  Rick Meeker

  Neuroprotective and anti-inflammatory actions of novel growth factor mimetics

  1/1/2007 - 12/31/2009

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 32,850.00

• 281.

  Kevin Robertson

  NEUROLOGIC AIDS RESEARCH CONSORTIUM-Related to 5-43020

  1/1/2007 - 12/31/2007

  Sponsor: Washington University in Saint Louis

  Funding: $ 25,463.00

• 282.

  Kevin Robertson

  NEUROLOGIC AIDS RESEARCH CONSORTIUM-RELATED TO 5-42503

  1/1/2007 - 12/31/2008

  Sponsor: Washington University in Saint Louis

  Funding: $ 2,920.00

• 283.

  Kevin Robertson

  NEUROLOGIC AIDS RESEARCH CONSORTIUM-RELATED TO 5-42503

  1/1/2007 - 12/31/2008

  Sponsor: Washington University in Saint Louis

  Funding: $ 1,752.00

• 284.

  David Huang; Souvik Sen

  INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL- A phase III, random

  12/1/2006 - 7/31/2015

  Sponsor: University of Cincinnati

  Funding: $ 11,562.00

• 285.

  David Huang; Souvik Sen

  INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL- A phase III, random

  12/1/2006 - 7/31/2015

  Sponsor: University of Cincinnati

  Funding: $ 11,408.00

• 286.

  David Huang; Souvik Sen

  INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL- A phase III, random

  12/1/2006 - 7/31/2015

  Sponsor: University of Cincinnati

  Funding: $ 11,408.00

• 287.

  David Huang; Souvik Sen

  INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL- A phase III, random

  12/1/2006 - 7/31/2015

  Sponsor: University of Cincinnati

  Funding: $ 19,600.00

• 288.

  David Huang

  INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL- A phase III, random

  12/1/2006 - 7/31/2015

  Sponsor: University of Cincinnati

  Funding: $ 939.00

• 289.

  David Huang

  INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL- A phase III, random

  12/1/2006 - 7/31/2015

  Sponsor: University of Cincinnati

  Funding: $ 939.00

• 290.

  Dinggang Shen; Daniel Kaufer; J Smith; Hongtu Zhu

  Development and Dissemination of Robust Brain MRI Measurement Tools

  12/1/2006 - 8/31/2016

  Sponsor: NIH National Institute of Biomedical Imaging and Bioengineering

  Funding: $ 531,904.00

• 291.

  John Mann

  Craniosacral Therapy in Migraine: Feasability Study

  9/30/2006 - 8/31/2009

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 292,000.00

• 292.

  John Mann; Remy Coeytaux; Susan Gaylord; Chirayath Suchindran; Kim Faurot

  Craniosacral Therapy in Migraine: Feasability Study

  9/30/2006 - 8/31/2009

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 283,532.00

• 293.

  Susan Gaylord; John Mann; Olafur Palsson; William Whitehead; Rebecca Coble

  Mindfulness for Irritable Bowel Syndrome

  9/30/2006 - 8/31/2010

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 212,649.00

• 294.

  Susan Gaylord; John Mann; William Whitehead

  Mindfulness for Irritable Bowel Syndrome

  9/30/2006 - 8/31/2010

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 138,931.00

• 295.

  Annelies Van Rie; Kevin Robertson

  Pediatric HIV-encephalopathy in DRC: effect of ART & role of compartmentalizatio

  8/1/2006 - 5/31/2013

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 445,191.00

• 296.

  Annelies Van Rie; Kevin Robertson

  Pediatric HIV-encephalopathy in DRC: effect of ART & role of compartmentalizatio

  8/1/2006 - 5/31/2013

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 421,443.00

• 297.

  Annelies Van Rie; Kevin Robertson

  Pediatric HIV-encephalopathy in DRC: effect of ART & role of compartmentalizatio

  8/1/2006 - 5/31/2013

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 410,275.00

• 298.

  Silva Markovic-Plese

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 5,000.00

• 299.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 4,500.00

• 300.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 3,957.00

• 301.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 3,920.00

• 302.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 13,238.00

• 303.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 1,782.00

• 304.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 26,603.00

• 305.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 2,512.00

• 306.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 6,472.00

• 307.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 570.00

• 308.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 2,854.00

• 309.

  Silva Markovic-Plese; Syndee Givre; Xuemei Huang; Herbert Krob; John Mann; Cynthia Kenan; Joan Olive

  24-month dbl-blind, random, multicntr, study of 0.5 mg & 1.25 mg fingolimod (FTY

  7/24/2006 - 3/8/2010

  Sponsor: Industry Sponsor

  Funding: $ 3,437.00

• 310.

  Joseph Eron; Kevin Robertson; Colin Hall

  BRS-ACURE-Q-06-00160 Master Agreement

  7/1/2006 - 5/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 269,761.00

• 311.

  Joseph Eron; Kevin Robertson; Colin Hall

  BRS-ACURE-Q-06-00160 Master Agreement

  7/1/2006 - 5/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 269,761.00

• 312.

  Joseph Eron; Kevin Robertson

  BRS-ACURE-Q-06-00160 Master Agreement

  7/1/2006 - 5/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 38,890.00

• 313.

  Joseph Eron; Kevin Robertson

  BRS-ACURE-Q-06-00160 Master Agreement

  7/1/2006 - 5/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 153,638.00

• 314.

  Joseph Eron; Kevin Robertson

  BRS-ACURE-Q-06-00160 Master Agreement

  7/1/2006 - 5/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 54,463.00

• 315.

  Joseph Eron; Kevin Robertson; Ronald Swanstrom

  BRS-ACURE-Q-06-00160 Master Agreement

  7/1/2006 - 5/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 208,295.00

• 316.

  David Huang; Souvik Sen

  93.853 Albumin in Acute Stroke (ALIAS) Trial: Phase III Randomized Multicent

  6/1/2006 - 5/31/2012

  Sponsor: University of Miami

  Funding: $ 24,820.00

• 317.

  David Huang; Souvik Sen

  93.853 Albumin in Acute Stroke (ALIAS) Trial: Phase III Randomized Multicent

  6/1/2006 - 5/31/2012

  Sponsor: University of Miami

  Funding: $ 13,870.00

• 318.

  David Huang; Souvik Sen

  93.853 Albumin in Acute Stroke (ALIAS) Trial: Phase III Randomized Multicent

  6/1/2006 - 5/31/2012

  Sponsor: University of Miami

  Funding: $ 3,650.00

• 319.

  David Huang; Souvik Sen

  93.853 Albumin in Acute Stroke (ALIAS) Trial: Phase III Randomized Multicent

  6/1/2006 - 5/31/2012

  Sponsor: University of Miami

  Funding: $ 8,760.00

• 320.

  David Huang; Souvik Sen

  93.853 Albumin in Acute Stroke (ALIAS) Trial: Phase III Randomized Multicent

  6/1/2006 - 5/31/2012

  Sponsor: University of Miami

  Funding: $ 18,250.00

• 321.

  David Huang

  93.853 Albumin in Acute Stroke (ALIAS) Trial: Phase III Randomized Multicent

  6/1/2006 - 5/31/2012

  Sponsor: University of Miami

  Funding: $ 41,440.00

• 322.

  Rick Meeker

  FELLOW:DEIRDRE KILLEBREW-Macrophages Role in the Development of HIV Lipoatrophy

  5/1/2006 - 4/30/2009

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 7,000.00

• 323.

  Rick Meeker

  FELLOW:DEIRDRE KILLEBREW-Machrophages Role in Development of HIV Lipoatrophy

  5/1/2006 - 4/30/2009

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 50,427.00

• 324.

  Kevin Kahn; Anne Calhoun; Alan Finkel; John Mann

  Random, Dbl-Blind, Single Dose, Evaluation of of Intravenous Lornoxicam in Acute Treatment of the Headache of Migraine

  3/8/2006 - 3/7/2009

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 325.

  David Huang

  Random, Dbl-Blind, Trial of Activated Recombinant Factor VII (NovoSeven/Niastase) in Accute Intracerebral Haemorrhage

  2/22/2006 - 2/21/2009

  Sponsor: Industry Sponsor

  Funding: $ 9,060.00

• 326.

  Bradley Vaughn

  Dbl-Blind Trial Comparing Efficacy, Tolerability & Safety of Monotherapy Topiramate vs Phenytoin in Subjs w/Seizures Indicative of New Onset Epil

  1/12/2006 - 1/11/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,618.00

• 327.

  Bradley Vaughn

  Dbl-Blind Trial Comparing Efficacy, Tolerability & Safety of Monotherapy Topiramate vs Phenytoin in Subjs w/Seizures Indicative of New Onset Epil

  1/12/2006 - 1/11/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,000.00

• 328.

  Bradley Vaughn; Melanie Adams; O'Neill D'Cruz; Robert Greenwood; Michael Tennison

  Dbl-Blind Trial Comparing Efficacy, Tolerability & Safety of Monotherapy Topiramate vs Phenytoin in Subjs w/Seizures Indicative of New Onset Epil

  1/12/2006 - 1/11/2009

  Sponsor: Industry Sponsor

  Funding: $ 8,217.00

• 329.

  Alan Finkel; Anne Calhoun; Kevin Kahn; John Mann

  Random, Dbl-Blind .... Stdy to Determine Consistency of Response for Trexima (sumatriptan 85mg/naproxen sodium 500 mg) Administered During

  10/28/2005 - 12/12/2006

  Sponsor: Industry Sponsor

  Funding: $ 10,029.00

• 330.

  Alan Finkel; Anne Calhoun; Kevin Kahn; John Mann

  Random, Dbl-Blind .... Stdy to Determine Consistency of Response for Trexima (sumatriptan 85mg/naproxen sodium 500 mg) Administered During

  10/28/2005 - 12/12/2006

  Sponsor: Industry Sponsor

  Funding: $ 3,737.00

• 331.

  Alan Finkel; Anne Calhoun; Kevin Kahn; John Mann

  Random, Dbl-Blind .... Stdy to Determine Consistency of Response for Trexima (sumatriptan 85mg/naproxen sodium 500 mg) Administered During

  10/28/2005 - 12/12/2006

  Sponsor: Industry Sponsor

  Funding: $ 7,000.00

• 332.

  Daniel Kaufer

  Random, .... Eval of Safety & Efficacy of Memantine in Patients w/Moderate-to-Severe Dementia of the Alzeheimer's Type

  9/22/2005 - 5/31/2007

  Sponsor: Industry Sponsor

  Funding: $ 819.00

• 333.

  William Maixner; Eric Bair; Luda Diatchenko; Pei Feng Lim; John Mann; Gary Slade; Shad Smith; William Whitehead

  Risk Factors for Onset and Persistence of TWD

  9/15/2005 - 7/31/2017

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 3,910,739.00

• 334.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 14,333.00

• 335.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 8,437.00

• 336.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 1,200.00

• 337.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 1,662.00

• 338.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 9,922.00

• 339.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 1,074.00

• 340.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 1,352.00

• 341.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 1,181.00

• 342.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 12,665.00

• 343.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 2,237.00

• 344.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 35,411.00

• 345.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 21,646.00

• 346.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 63.00

• 347.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 15,319.00

• 348.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 7,415.00

• 349.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 7,868.00

• 350.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 796.00

• 351.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 300.00

• 352.

  David Huang; Souvik Sen

  Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke

  8/31/2005 - 8/30/2011

  Sponsor: Industry Sponsor

  Funding: $ 12,410.00

• 353.

  Kevin Robertson

  NEUROLOGIC AIDS RESEARCH CONSORTIUM

  8/1/2005 - 12/31/2006

  Sponsor: Washington University in Saint Louis

  Funding: $ 21,098.00

• 354.

  Kevin Robertson

  NEUROLOGIC AIDS RESEARCH CONSORTIUM

  8/1/2005 - 12/31/2006

  Sponsor: Washington University in Saint Louis

  Funding: $ 10,731.00

• 355.

  David Huang

  CHIP in Murine Models of Cerebral Ischemia

  7/1/2005 - 7/31/2009

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 165,701.00

• 356.

  David Huang

  CHIP in Murine Models of Cerebral Ischemia

  7/1/2005 - 7/31/2009

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 166,576.00

• 357.

  David Huang

  CHIP in Murine Models of Cerebral Ischemia

  7/1/2005 - 7/31/2009

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 166,576.00

• 358.

  David Huang

  CHIP in Murine Models of Cerebral Ischemia

  7/1/2005 - 7/31/2009

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 166,576.00

• 359.

  Silva Markovic-Plese; Sunil Chauhan; Ajmal Gilani; John Mann; Leslie Rucker; Jennifer Smrtka

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 13,538.00

• 360.

  Silva Markovic-Plese; Sunil Chauhan; Ajmal Gilani; John Mann; Leslie Rucker; Jennifer Smrtka

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 29,412.00

• 361.

  Silva Markovic-Plese

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 26,413.00

• 362.

  Silva Markovic-Plese; Sunil Chauhan; Ajmal Gilani; John Mann; Leslie Rucker; Jennifer Smrtka

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 31,471.00

• 363.

  Silva Markovic-Plese; Sunil Chauhan; Ajmal Gilani; John Mann; Leslie Rucker; Jennifer Smrtka

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 26,542.00

• 364.

  Silva Markovic-Plese; Sunil Chauhan; Ajmal Gilani; John Mann; Leslie Rucker; Jennifer Smrtka

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 468.00

• 365.

  Silva Markovic-Plese; Sunil Chauhan; Ajmal Gilani; John Mann; Leslie Rucker; Jennifer Smrtka

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 61,864.00

• 366.

  Silva Markovic-Plese; Teresa Harper

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 250.00

• 367.

  Silva Markovic-Plese; Sunil Chauhan; Ajmal Gilani; John Mann; Leslie Rucker; Jennifer Smrtka

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 8,754.00

• 368.

  Silva Markovic-Plese; Sunil Chauhan; Ajmal Gilani; John Mann; Leslie Rucker; Jennifer Smrtka

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 20,603.00

• 369.

  Silva Markovic-Plese; Sunil Chauhan; Ajmal Gilani; John Mann; Leslie Rucker; Jennifer Smrtka

  Multi-Center ... Study Assess Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated w/Glatiramer Acetate (GAj)

  6/20/2005 - 6/19/2010

  Sponsor: Industry Sponsor

  Funding: $ 33,518.00

• 370.

  Rick Meeker; Frank Longo

  NGF Small Molecule Mimetics: Preclinical Studies

  4/1/2005 - 4/30/2009

  Sponsor: Institute for the Study of Aging (ISOA)

  Funding: $ 150,000.00

• 371.

  Rick Meeker; Frank Longo

  NGF Small Molecule Mimetics: Preclinical Studies

  4/1/2005 - 4/30/2009

  Sponsor: Institute for the Study of Aging (ISOA)

  Funding: $ 25,000.00

• 372.

  William Snider; Mark Walzer

  Mark Walzer/Fellow Role of ILK in Sensory Axon Development and Regeneration (Postdoctoral Fellowship)

  3/18/2005 - 3/17/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 48,796.00

• 373.

  William Snider; Mark Walzer

  Mark A. Walzer/Fellow Role of ILK in Sensory Axon Development and Regeneration

  3/18/2005 - 3/17/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 43,976.00

• 374.

  Bradley Vaughn; Megdad Zaatreh

  Multicenter, .... Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Subjects w/Partial Seizures

  3/10/2005 - 7/31/2007

  Sponsor: Industry Sponsor

  Funding: $ 4,990.00

• 375.

  Bradley Vaughn; Megdad Zaatreh

  Multicenter, .... Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Subjects w/Partial Seizures

  3/10/2005 - 7/31/2007

  Sponsor: Industry Sponsor

  Funding: $ 1,000.00

• 376.

  Bob Greenwood

  Multi -Ctr, Opn-Lbl, Long-Term, Follow-Up Stdy of Safety & Efficacy of Levetiracetam in Children with Partial Onset Seizures

  1/26/2005 - 1/25/2007

  Sponsor: Industry Sponsor

  Funding: $ 4,125.00

• 377.

  Bob Greenwood

  Dbl-Blind .... In-Patient, Maximum 34-Day Stdy of Levetiracetam Oral Solution (20-50mg/kg/day) as Adjunc Trtmt of Refractory Partial Onset Seiz in Pe

  1/26/2005 - 1/25/2007

  Sponsor: Industry Sponsor

  Funding: $ 3,000.00

• 378.

  John Mann; Aysha Akhtar

  End-of-Life Care Preferences of ALS Patients and Their Physicians' Assumptions: A Pilot Study

  1/1/2005 - 12/31/2005

  Sponsor: Greenwall Foundation

  Funding: $ 4,875.00

• 379.

  William Snider

  Roles of GSK-3B & ILK in Regenerative Axon Growth

  12/15/2004 - 1/14/2007

  Sponsor: Christopher Reeve Paralysis Foundation

  Funding: $ 75,000.00

• 380.

  William Snider

  Roles of GSK-3B & ILK in Regenerative Axon Growth

  12/15/2004 - 1/14/2007

  Sponsor: Christopher Reeve Paralysis Foundation

  Funding: $ 75,000.00

• 381.

  Silva Markovic-Plese

  Early IFNbeta-1a & Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

  12/8/2004 - 3/31/2011

  Sponsor: Industry Sponsor

  Funding: $ 100,504.00

• 382.

  Silva Markovic-Plese

  Early IFNbeta-1a & Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

  12/8/2004 - 3/31/2011

  Sponsor: Industry Sponsor

  Funding: $ 19,027.00

• 383.

  Silva Markovic-Plese

  Early IFNbeta-1a & Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

  12/8/2004 - 3/31/2011

  Sponsor: Industry Sponsor

  Funding: $ 111,340.00

• 384.

  Silva Markovic-Plese

  Early IFNbeta-1a & Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

  12/8/2004 - 3/31/2011

  Sponsor: Industry Sponsor

  Funding: $ 62,300.00

• 385.

  Silva Markovic-Plese

  Early IFNbeta-1a & Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

  12/8/2004 - 3/31/2011

  Sponsor: Industry Sponsor

  Funding: $ 29,267.00

• 386.

  Alexander Troster

  Ropinirole's Effects on Working Memory, Mood, & Quality of Life in Early Parkinson's Disease: A Random, Dbl-Blind, Placebo Controlled Study

  12/1/2004 - 12/1/2006

  Sponsor: Industry Sponsor

  Funding: $ 37,500.00

• 387.

  Alexander Troster

  Ropinirole's Effects on Working Memory, Mood, & Quality of Life in Early Parkinson's Disease: A Random, Dbl-Blind, Placebo Controlled Study

  12/1/2004 - 12/1/2006

  Sponsor: Industry Sponsor

  Funding: $ 5,000.00

• 388.

  Sheryl Zimmerman; Daniel Kaufer; Philip Sloane

  Using the Minimum Data Set Cognition Scale (MDS-COGS) to Detect Undiagnosed Dementia in Assisted Living

  12/1/2004 - 6/30/2006

  Sponsor: Industry Sponsor

  Funding: $ 250,000.00

• 389.

  Sheryl Zimmerman; Daniel Kaufer; Philip Sloane

  Using the Minimum Data Set Cognition Scale (MDS-COGS) to Detect Undiagnosed Dementia in Assisted Living

  12/1/2004 - 6/30/2006

  Sponsor: Industry Sponsor

  Funding: $ 14,271.00

• 390.

  Heidi Roth

  Galantamine Treatment for Nonfluenht Aphasia in Stroke Patients

  10/21/2004 - 12/31/2007

  Sponsor: Industry Sponsor

  Funding: $ 13,000.00

• 391.

  Heidi Roth

  Galantamine Treatment for Nonfluenht Aphasia in Stroke Patients

  10/21/2004 - 12/31/2007

  Sponsor: Industry Sponsor

  Funding: $ 13,000.00

• 392.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 9,600.00

• 393.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 4,800.00

• 394.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 9,600.00

• 395.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 1,860.00

• 396.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 4,080.00

• 397.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 13,929.00

• 398.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 5,300.00

• 399.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 9,660.00

• 400.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 9,600.00

• 401.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 1,860.00

• 402.

  Silva Markovic-Plese

  Multi Ctr, Rand, .... Stdy of AVONEX Comp w/AVONEX in Combination w/Oral Methotrexade, Intravenous Methylprednisolone or Both in Subs w/MS (ACT)

  10/21/2004 - 9/1/2006

  Sponsor: Cleveland Clinic Foundation

  Funding: $ 3,000.00

• 403.

  Silva Markovic-Plese

  Early IFNb-1a & Simvastatin Combination Therapy in Clinically Isolate Syndrome Suggestive of Multiple Sclerosis

  10/11/2004 - 10/10/2006

  Sponsor: Industry Sponsor

  Funding: $ 87,246.00

• 404.

  Silva Markovic-Plese

  Early IFNb-1a & Simvastatin Combination Therapy in Clinically Isolate Syndrome Suggestive of Multiple Sclerosis

  10/11/2004 - 10/10/2006

  Sponsor: Industry Sponsor

  Funding: $ 2,842.00

• 405.

  Silva Markovic-Plese

  Early IFNb-1a & Simvastatin Combination Therapy in Clinically Isolate Syndrome Suggestive of Multiple Sclerosis

  10/11/2004 - 10/10/2006

  Sponsor: Industry Sponsor

  Funding: $ 9,393.00

• 406.

  Silva Markovic-Plese

  Early IFNb-1a & Simvastatin Combination Therapy in Clinically Isolate Syndrome Suggestive of Multiple Sclerosis

  10/11/2004 - 10/10/2006

  Sponsor: Industry Sponsor

  Funding: $ 1,078.00

• 407.

  Ana Felix

  Dbl-Blind, Rand, Ph IIb/III Stdy to Assess Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

  9/27/2004 - 12/31/2006

  Sponsor: Industry Sponsor

  Funding: $ 12,000.00

• 408.

  Ana Felix

  Dbl-Blind, Rand, Ph IIb/III Stdy to Assess Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

  9/27/2004 - 12/31/2006

  Sponsor: Industry Sponsor

  Funding: $ 5,400.00

• 409.

  Ana Felix

  Dbl-Blind, Rand, Ph IIb/III Stdy to Assess Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

  9/27/2004 - 12/31/2006

  Sponsor: Industry Sponsor

  Funding: $ 13,000.00

• 410.

  Ana Felix

  Dbl-Blind, Rand, Ph IIb/III Stdy to Assess Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

  9/27/2004 - 12/31/2006

  Sponsor: Industry Sponsor

  Funding: $ 14,500.00

• 411.

  Ana Felix

  Dbl-Blind, Rand, Ph IIb/III Stdy to Assess Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

  9/27/2004 - 12/31/2006

  Sponsor: Industry Sponsor

  Funding: $ 14,800.00

• 412.

  Ana Felix

  Dbl-Blind, Rand, Ph IIb/III Stdy to Assess Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

  9/27/2004 - 12/31/2006

  Sponsor: Industry Sponsor

  Funding: $ 11,800.00

• 413.

  Ana Felix

  Dbl-Blind, Rand, Ph IIb/III Stdy to Assess Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

  9/27/2004 - 12/31/2006

  Sponsor: Industry Sponsor

  Funding: $ 21,000.00

• 414.

  Ana Felix

  Dbl-Blind, Rand, Ph IIb/III Stdy to Assess Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

  9/27/2004 - 12/31/2006

  Sponsor: Industry Sponsor

  Funding: $ 17,500.00

• 415.

  Ana Felix

  Dbl-Blind, Rand, Ph IIb/III Stdy to Assess Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke

  9/27/2004 - 12/31/2006

  Sponsor: Industry Sponsor

  Funding: $ 3,500.00

• 416.

  William Snider

  The GSK-3B/APC Pathway in Development and Regenerative Axon Growth

  9/15/2004 - 1/31/2010

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 337,625.00

• 417.

  William Snider

  The GSK-3B/APC Pathway in Development and Regenerative Axon Growth

  9/15/2004 - 1/31/2010

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 337,625.00

• 418.

  William Snider

  The GSK-3B/APC Pathway in Development and Regenerative Axon Growth

  9/15/2004 - 1/31/2010

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 329,691.00

• 419.

  William Snider

  The GSK-3B/APC Pathway in Development and Regenerative Axon Growth

  9/15/2004 - 1/31/2010

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 320,130.00

• 420.

  William Snider

  The GSK-3B/APC Pathway in Development and Regenerative Axon Growth

  9/15/2004 - 1/31/2010

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 320,130.00

• 421.

  William Snider; Eva Anton

  GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal

  9/15/2004 - 1/31/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 397,432.00

• 422.

  William Snider

  GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal

  9/15/2004 - 1/31/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 357,689.00

• 423.

  William Snider

  GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal

  9/15/2004 - 1/31/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 35,769.00

• 424.

  William Snider; Eva Anton

  GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal

  9/15/2004 - 1/31/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 393,458.00

• 425.

  William Snider; Eva Anton

  GSK-3 is a Master Regulator of Neural Progenitor Self-Renewal

  9/15/2004 - 1/31/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 354,110.00

• 426.

  Michael Tennison

  Opn-Lbl Eval of LAMICTAL (lamotrigine) Monotherapy for Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents

  9/1/2004 - 1/19/2006

  Sponsor: Industry Sponsor

  Funding: $ 7,213.00

• 427.

  Michael Tennison

  Opn-Lbl Eval of LAMICTAL (lamotrigine) Monotherapy for Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents

  9/1/2004 - 1/19/2006

  Sponsor: Industry Sponsor

  Funding: $ 3,376.00

• 428.

  Michael Tennison

  Opn-Lbl Eval of LAMICTAL (lamotrigine) Monotherapy for Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents

  9/1/2004 - 1/19/2006

  Sponsor: Industry Sponsor

  Funding: $ 7,513.00

• 429.

  Michael Tennison

  Opn-Lbl Eval of LAMICTAL (lamotrigine) Monotherapy for Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents

  9/1/2004 - 1/19/2006

  Sponsor: Industry Sponsor

  Funding: $ 5,215.00

• 430.

  Michael Tennison

  Opn-Lbl Eval of LAMICTAL (lamotrigine) Monotherapy for Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents

  9/1/2004 - 1/19/2006

  Sponsor: Industry Sponsor

  Funding: $ 3,601.00

• 431.

  Michael Tennison

  Opn-Lbl Eval of LAMICTAL (lamotrigine) Monotherapy for Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents

  9/1/2004 - 1/19/2006

  Sponsor: Industry Sponsor

  Funding: $ 1,051.00

• 432.

  Michael Tennison

  Opn-Lbl Eval of LAMICTAL (lamotrigine) Monotherapy for Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents

  9/1/2004 - 1/19/2006

  Sponsor: Industry Sponsor

  Funding: $ 1,429.00

• 433.

  Michael Tennison

  Opn-Lbl Eval of LAMICTAL (lamotrigine) Monotherapy for Treatment of Newly-Diagnosed Typical Absence Seizures in Children and Adolescents

  9/1/2004 - 1/19/2006

  Sponsor: Industry Sponsor

  Funding: $ 6,624.00

• 434.

  James Howard

  Rand, Dbl-Blind ..... 36 Wk Trial to Assess the E & S of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symtom Control W/Reduced Corticost

  8/2/2004 - 3/1/2006

  Sponsor: Industry Sponsor

  Funding: $ 12,811.00

• 435.

  James Howard

  Rand, Dbl-Blind ..... 36 Wk Trial to Assess the E & S of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symtom Control W/Reduced Corticost

  8/2/2004 - 3/1/2006

  Sponsor: Industry Sponsor

  Funding: $ 16,721.00

• 436.

  James Howard

  Rand, Dbl-Blind ..... 36 Wk Trial to Assess the E & S of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symtom Control W/Reduced Corticost

  8/2/2004 - 3/1/2006

  Sponsor: Industry Sponsor

  Funding: $ 2,720.00

• 437.

  Bradley Vaughn

  Effects of Treating Obstructive Sleep Apnea in Epilepsy

  8/1/2004 - 12/31/2005

  Sponsor: Vanderbilt University Medical Center

  Funding: $ 67,078.00

• 438.

  Kevin Robertson

  Neurologic AIDS Research Consortium

  8/1/2004 - 7/31/2005

  Sponsor: Washington University in Saint Louis

  Funding: $ 25,463.00

• 439.

  Kevin Robertson

  Neurologic AIDS Research Consortium

  8/1/2004 - 7/31/2005

  Sponsor: Washington University in Saint Louis

  Funding: $ 6,313.00

• 440.

  David Huang

  CHIP in Murine Models of Cerebral Ischemia (National Scientist Development Grant)

  7/1/2004 - 6/30/2008

  Sponsor: American Heart Association (AHA)

  Funding: $ 65,000.00

• 441.

  David Huang

  CHIP in Murine Models of Cerebral Ischemia (National Scientist Development Grant)

  7/1/2004 - 6/30/2008

  Sponsor: American Heart Association (AHA)

  Funding: $ 65,000.00

• 442.

  Ana Felix

  Opn Lbl, Rand, PG, MC Stdy to Eval E & S of Enoxaparin vs Unfractionated Heparin in Prev of Venous Thromboembolism in Pts follow Acute Ischemic Stro

  5/10/2004 - 5/10/2006

  Sponsor: Industry Sponsor

  Funding: $ 15,000.00

• 443.

  Ana Felix

  Opn Lbl, Rand, PG, MC Stdy to Eval E & S of Enoxaparin vs Unfractionated Heparin in Prev of Venous Thromboembolism in Pts follow Acute Ischemic Stro

  5/10/2004 - 5/10/2006

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 444.

  Ana Felix

  Opn Lbl, Rand, PG, MC Stdy to Eval E & S of Enoxaparin vs Unfractionated Heparin in Prev of Venous Thromboembolism in Pts follow Acute Ischemic Stro

  5/10/2004 - 5/10/2006

  Sponsor: Industry Sponsor

  Funding: $ 3,000.00

• 445.

  Ana Felix

  Opn Lbl, Rand, PG, MC Stdy to Eval E & S of Enoxaparin vs Unfractionated Heparin in Prev of Venous Thromboembolism in Pts follow Acute Ischemic Stro

  5/10/2004 - 5/10/2006

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 446.

  Daniel Kaufer

  Cognitive Phenotyping of Parkinsonian Dementias

  5/1/2004 - 4/30/2006

  Sponsor: Duke University

  Funding: $ 30,000.00

• 447.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 12,218.00

• 448.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 11,843.00

• 449.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 12,781.00

• 450.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 4,000.00

• 451.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 750.00

• 452.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 7,687.00

• 453.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 15,187.00

• 454.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 10,913.00

• 455.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 5,875.00

• 456.

  Daniel Kaufer

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 375.00

• 457.

  Daniel Kaufer; Charlene Riedel-Leo

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 247.00

• 458.

  Daniel Kaufer; Charlene Riedel-Leo

  Multicenter, Dbl-Blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function in Alzheimer's Di

  4/1/2004 - 12/31/2008

  Sponsor: Georgetown University

  Funding: $ 1,252.00

• 459.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 3,000.00

• 460.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 452.00

• 461.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 3,680.00

• 462.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 3,872.00

• 463.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 736.00

• 464.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 10,856.00

• 465.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 466.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 5,304.00

• 467.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,400.00

• 468.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 5,094.00

• 469.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 6,121.00

• 470.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,676.00

• 471.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,205.00

• 472.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,536.00

• 473.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,252.00

• 474.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 10,772.00

• 475.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,776.00

• 476.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 3,342.00

• 477.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,773.00

• 478.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 3,768.00

• 479.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,548.00

• 480.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 1,544.00

• 481.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,293.00

• 482.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 1,104.00

• 483.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,613.00

• 484.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 880.00

• 485.

  David Huang; Souvik Sen

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 1,529.00

• 486.

  David Huang; Souvik Sen; Kim Holzmacher; Susan Wilson

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 1,596.00

• 487.

  David Huang; Souvik Sen; Kim Holzmacher; Susan Wilson

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 5,400.00

• 488.

  David Huang; Souvik Sen; Kim Holzmacher; Susan Wilson

  DB, Active & Placebo-Controlled Study of Aggrenox vs. clopidogrel + aspirin, with & without Micardis in Stroke

  3/23/2004 - 1/1/2009

  Sponsor: Industry Sponsor

  Funding: $ 8,648.00

• 489.

  William Snider; Fengquan Zhou

  Signal transduction and cytoskeletal mechanisms of axon regenetation

  1/1/2004 - 12/31/2004

  Sponsor: Spinal Cord Research Foundation

  Funding: $ 50,000.00

• 490.

  Ana Felix

  Prospective, MC, Ran, Control Trial to Eval the s & e of the Starflex Septal Closure System Vs Best Medical Therapy in Patients with a stroke &/or tra

  10/28/2003 - 12/31/2009

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 491.

  Ana Felix

  Prospective, MC, Ran, Control Trial to Eval the s & e of the Starflex Septal Closure System Vs Best Medical Therapy in Patients with a stroke &/or tra

  10/28/2003 - 12/31/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 492.

  Ana Felix

  Prospective, MC, Ran, Control Trial to Eval the s & e of the Starflex Septal Closure System Vs Best Medical Therapy in Patients with a stroke &/or tra

  10/28/2003 - 12/31/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 493.

  Ana Felix

  Prospective, MC, Ran, Control Trial to Eval the s & e of the Starflex Septal Closure System Vs Best Medical Therapy in Patients with a stroke &/or tra

  10/28/2003 - 12/31/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,042.00

• 494.

  Ana Felix

  Prospective, MC, Ran, Control Trial to Eval the s & e of the Starflex Septal Closure System Vs Best Medical Therapy in Patients with a stroke &/or tra

  10/28/2003 - 12/31/2009

  Sponsor: Industry Sponsor

  Funding: $ 58.00

• 495.

  Ana Felix

  Prospective, MC, Ran, Control Trial to Eval the s & e of the Starflex Septal Closure System Vs Best Medical Therapy in Patients with a stroke &/or tra

  10/28/2003 - 12/31/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,000.00

• 496.

  Ana Felix

  Prospective, MC, Ran, Control Trial to Eval the s & e of the Starflex Septal Closure System Vs Best Medical Therapy in Patients with a stroke &/or tra

  10/28/2003 - 12/31/2009

  Sponsor: Industry Sponsor

  Funding: $ 8,000.00

• 497.

  Ana Felix; Souvik Sen; Frank Doggett; Susan Wilson

  Prospective, MC, Ran, Control Trial to Eval the s & e of the Starflex Septal Closure System Vs Best Medical Therapy in Patients with a stroke &/or tra

  10/28/2003 - 12/31/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,000.00

• 498.

  Kevin Robertson; Colin Hall

  Aactg Protocol A5199; International Neurological Study

  10/15/2003 - 12/31/2007

  Sponsor: Industry Sponsor

  Funding: $ 269,761.00

• 499.

  Kevin Robertson; Colin Hall

  Aactg Protocol A5199; International Neurological Study

  10/15/2003 - 12/31/2007

  Sponsor: Industry Sponsor

  Funding: $ 269,761.00

• 500.

  Kevin Robertson; Colin Hall

  Aactg Protocol A5199; International Neurological Study

  10/15/2003 - 12/31/2007

  Sponsor: Industry Sponsor

  Funding: $ 269,761.00

• 501.

  John Mann

  Korean Acupuncture in Central Nervous System Disorders

  9/26/2003 - 3/31/2006

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 133,120.00

• 502.

  John Mann

  Korean Acupuncture in Central Nervous System Disorders

  9/26/2003 - 3/31/2006

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 121,620.00

• 503.

  Silva Markovic-Plese

  The Mechanisms of Autoimmune Response Initiation in MS

  8/15/2003 - 7/31/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 165,618.00

• 504.

  Silva Markovic-Plese

  The Mechanisms of Autoimmune Response Initiation in MS

  8/15/2003 - 7/31/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 165,618.00

• 505.

  Silva Markovic-Plese

  The Mechanisms of Autoimmune Response Initiation in MS

  8/15/2003 - 7/31/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 165,618.00

• 506.

  Silva Markovic-Plese

  The Mechanisms of Autoimmune Response Initiation in MS

  8/15/2003 - 7/31/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 165,618.00

• 507.

  Silva Markovic-Plese

  The Mechanisms of Autoimmune Response Initiation in MS

  8/15/2003 - 7/31/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 165,618.00

• 508.

  C.J. Malanga

  Effect of prenatal cocaine exposure on brain reward

  8/10/2003 - 4/30/2009

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 144,524.00

• 509.

  C.J. Malanga

  Effect of prenatal cocaine exposure on brain reward

  8/10/2003 - 4/30/2009

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 88,134.00

• 510.

  C.J. Malanga

  Effect of prenatal cocaine exposure on brain reward

  8/10/2003 - 4/30/2009

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 147,308.00

• 511.

  C.J. Malanga

  Effect of prenatal cocaine exposure on brain reward

  8/10/2003 - 4/30/2009

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 152,414.00

• 512.

  Bradley Vaughn

  Effects of Treating Obstructive Sleep Apnea In Epilepsy

  8/1/2003 - 7/31/2004

  Sponsor: Vanderbilt University Medical Center

  Funding: $ 64,474.00

• 513.

  Kevin Robertson

  Neurologic AIDS Research Consortium

  8/1/2003 - 7/31/2004

  Sponsor: Washington University in Saint Louis

  Funding: $ 10,913.00

• 514.

  John Mann

  Painful HIV Neuropathy: Treatment with Alpha-Lipoic Acid

  7/15/2003 - 3/31/2006

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 182,500.00

• 515.

  John Mann

  Painful HIV Neuropathy: Treatment with Alpha-Lipoic Acid

  7/15/2003 - 3/31/2006

  Sponsor: NIH National Center for Complementary and Alternative Medicine

  Funding: $ 182,500.00

• 516.

  William Snider

  UNC Neuroscience Center Research Cores--Non-Working Prime

  7/1/2003 - 6/30/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 654,751.00

• 517.

  William Snider

  UNC Neuroscience Center Research Cores--Non-Working Prime

  7/1/2003 - 6/30/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 730,000.00

• 518.

  William Snider

  UNC Neuroscience Center Research Cores--Non-Working Prime

  7/1/2003 - 6/30/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 730,000.00

• 519.

  William Snider

  UNC Neuroscience Center Research Cores--Non-Working Prime

  7/1/2003 - 6/30/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 730,000.00

• 520.

  William Snider

  UNC Neuroscience Center Research Cores--Non-Working Prime

  7/1/2003 - 6/30/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 708,829.00

• 521.

  William Snider

  UNC Neuroscience Center Research Cores

  7/1/2003 - 11/30/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 737,500.00

• 522.

  William Snider

  UNC Neuroscience Center Research Cores

  7/1/2003 - 11/30/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 740,000.00

• 523.

  William Snider; Eva Anton; Jay Brenman; Mohanish Deshmukh; Larysa Pevny; Franck Polleux; Kirk Wilhelmsen; Mark Zylka

  UNC Neuroscience Center Research Cores

  7/1/2003 - 11/30/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 740,000.00

• 524.

  William Snider

  UNC Neuroscience Center Research Cores

  7/1/2003 - 11/30/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 308,333.00

• 525.

  William Snider; Eva Anton; Jay Brenman; Mohanish Deshmukh; Larysa Pevny; Mark Zylka

  UNC Neuroscience Center Research Cores

  7/1/2003 - 11/30/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 666,000.00

• 526.

  William Snider; Eva Anton; Jay Brenman; Mohanish Deshmukh; Larysa Pevny; Mark Zylka

  UNC Neuroscience Center Research Cores

  7/1/2003 - 11/30/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 74,000.00

• 527.

  William Snider; Eva Anton; Mohanish Deshmukh; Mark Zylka

  UNC Neuroscience Center Research Cores

  7/1/2003 - 11/30/2013

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 666,001.00

• 528.

  Bradley Vaughn

  PRTCL N01085 A 9-11 Week MC, R, DB, PC, PG Study to Determine the Effects of Adjunctive Levetiracetam on the Sleep Architecture of Adult Subject (18-4

  5/21/2003 - 5/20/2004

  Sponsor: Industry Sponsor

  Funding: $ 14,604.00

• 529.

  Bradley Vaughn

  PRTCL N01085 A 9-11 Week MC, R, DB, PC, PG Study to Determine the Effects of Adjunctive Levetiracetam on the Sleep Architecture of Adult Subject (18-4

  5/21/2003 - 5/20/2004

  Sponsor: Industry Sponsor

  Funding: $ 1,500.00

• 530.

  Bob Greenwood

  PRTCL: SPD 433.401: MC, OL, PIV Stdy to Assess the T, S, & E of Switching fr Caramazepine Immediate Release and Liquid Formulation to Carbatrol Exte

  4/7/2003 - 6/30/2003

  Sponsor: Industry Sponsor

  Funding: $ 2,242.00

• 531.

  Sten Solander; Ana Felix; Souvik Sen

  PRTCL US-TR-001 A Multi-Center Controlled clinical Trial to Evaluate the Concentric Retriever System. A Phase II Study to Evaluate the Safety and Effi

  4/3/2003 - 4/2/2004

  Sponsor: Industry Sponsor

  Funding: $ 5,292.00

• 532.

  Sten Solander; Ana Felix; Souvik Sen

  PRTCL US-TR-001 A Multi-Center Controlled clinical Trial to Evaluate the Concentric Retriever System. A Phase II Study to Evaluate the Safety and Effi

  4/3/2003 - 4/2/2004

  Sponsor: Industry Sponsor

  Funding: $ 3,014.00

• 533.

  Sten Solander; Ana Felix; Souvik Sen

  PRTCL US-TR-001 A Multi-Center Controlled clinical Trial to Evaluate the Concentric Retriever System. A Phase II Study to Evaluate the Safety and Effi

  4/3/2003 - 4/2/2004

  Sponsor: Industry Sponsor

  Funding: $ 750.00

• 534.

  William Maixner; Eric Bair; Luda Diatchenko; Greg Essick; Rick Gracely; Joanne Jordan; Pei Feng Lim; John Mann; Andrea Neely; Gary Slade; William Whitehead; Denniz Zolnoun

  Complex Persistent Pain Conditions: Unique & Shared Pathways of Vulnerability

  3/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 1,221,031.00

• 535.

  William Maixner; Luda Diatchenko; Greg Essick; Rick Gracely; John Mann; Andrea Neely; Gary Slade; Shad Smith; Mark Tommerdahl; William Whitehead; Denniz Zolnoun

  Complex Persistent Pain Conditions: Unique & Shared Pathways of Vulnerability

  3/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 1,193,592.00

• 536.

  William Maixner; Luda Diatchenko; Greg Essick; Rick Gracely; Pei Feng Lim; John Mann; Andrea Neely; Anne Sanders; Gary Slade; William Whitehead

  Complex Persistent Pain Conditions: Unique & Shared Pathways of Vulnerability

  3/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 1,172,907.00

• 537.

  William Snider; Fengquan Zhou

  Signal transduction and cytoskeletal mechanisms of axon regenetation

  1/1/2003 - 12/31/2003

  Sponsor: Spinal Cord Research Foundation

  Funding: $ 50,000.00

• 538.

  Bradley Vaughn

  Effects of Treating Obsctuctive Sleep Apnea in Epilepsy

  10/1/2002 - 7/31/2003

  Sponsor: University of Michigan (UMICH)

  Funding: $ 52,090.00

• 539.

  Ronald Swanstrom; Colin Hall; Rick Meeker; Kevin Robertson

  Role of Fitness in HIV Protease Inhibitor Resistance

  7/1/2002 - 6/30/2008

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 69,597.00

• 540.

  Ronald Swanstrom; Colin Hall; Rick Meeker; Kevin Robertson

  Role of Fitness in HIV Protease Inhibitor Resistance

  7/1/2002 - 6/30/2008

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 319,186.00

• 541.

  Ronald Swanstrom; Colin Hall; Rick Meeker; Kevin Robertson

  Role of Fitness in HIV Protease Inhibitor Resistance

  7/1/2002 - 6/30/2008

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 68,227.00

• 542.

  Rick Meeker

  Microglia & Choroid plexus macrophages in Neuro-Aids

  3/11/2002 - 2/28/2006

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 234,605.00

• 543.

  Rick Meeker

  Microglia & Choroid plexus macrophages in Neuro-Aids

  3/11/2002 - 2/28/2006

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 223,230.00

• 544.

  Rick Meeker

  Microglia & Choroid plexus macrophages in Neuro-Aids

  3/11/2002 - 2/28/2006

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 223,230.00

• 545.

  Rick Meeker

  Microglia & Choroid plexus macrophages in Neuro-Aids

  3/11/2002 - 2/28/2006

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 223,230.00

• 546.

  William Snider

  Identification of Novel Genes that Direct Regenerative Axon Growth

  12/15/2001 - 12/14/2003

  Sponsor: Christopher Reeve Paralysis Foundation

  Funding: $ 75,000.00

• 547.

  William Snider

  Identification of Novel Genes that Direct Regenerative Axon Growth

  12/15/2001 - 12/14/2002

  Sponsor: Christopher Reeve Paralysis Foundation

  Funding: $ 75,000.00

• 548.

  Susan Gaylord; John Mann

  Developing a Sustainable Market for Medicinal Herbs in NC

  12/1/2001 - 10/31/2004

  Sponsor: University of North Carolina General Administration (UNC GA)

  Funding: $ 200,000.00

• 549.

  William Powers

  CAROTID OCCLUSION SURGERY STUDY

  9/30/2001 - 11/30/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 4,244,832.00

• 550.

  William Powers

  CAROTID OCCLUSION SURGERY STUDY

  9/30/2001 - 11/30/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 3,147,859.00

• 551.

  William Powers

  CAROTID OCCLUSION SURGERY STUDY

  9/30/2001 - 11/30/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 3,466,168.00

• 552.

  William Powers

  CAROTID OCCLUSION SURGERY STUDY

  9/30/2001 - 11/30/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 385,130.00

• 553.

  William Powers

  CAROTID OCCLUSION SURGERY STUDY

  9/30/2001 - 11/30/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 9,719.00

• 554.

  William Powers

  CAROTID OCCLUSION SURGERY STUDY

  9/30/2001 - 11/30/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 1.00

• 555.

  Kevin Robertson

  Cerebrospinal Fluid HIV-1 and Cognitive Function

  5/1/2001 - 7/31/2003

  Sponsor: Washington University in Saint Louis

  Funding: $ 4,365.00

• 556.

  Rick Meeker

  Choroid plexus macrophages in FIV neuropathogenesis

  4/1/2001 - 2/28/2011

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 283,531.00

• 557.

  Rick Meeker

  Choroid plexus macrophages in FIV neuropathogenesis

  4/1/2001 - 2/28/2011

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 267,046.00

• 558.

  Rick Meeker

  Choroid plexus macrophages in FIV neuropathogenesis

  4/1/2001 - 2/28/2011

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 269,508.00

• 559.

  Rick Meeker

  Choroid plexus macrophages in FIV neuropathogenesis

  4/1/2001 - 2/28/2011

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 243,170.00

• 560.

  Rick Meeker

  Choroid plexus macrophages in FIV neuropathogenesis

  4/1/2001 - 2/28/2011

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 27,019.00

• 561.

  Bradley Vaughn

  Open-Label, Multi-Center, Randomized Trial To Evaluate The Development of Components of Polycystic Ovary Syndrome In Female Subjects With Newly ....

  3/28/2001 - 11/30/2002

  Sponsor: Industry Sponsor

  Funding: $ 1,500.00

• 562.

  Bradley Vaughn

  Open-Label, Multi-Center, Randomized Trial To Evaluate The Development of Components of Polycystic Ovary Syndrome In Female Subjects With Newly ....

  3/28/2001 - 11/30/2002

  Sponsor: Industry Sponsor

  Funding: $ 2,550.00

• 563.

  Bradley Vaughn

  Open-Label, Multi-Center, Randomized Trial To Evaluate The Development of Components of Polycystic Ovary Syndrome In Female Subjects With Newly ....

  3/28/2001 - 11/30/2002

  Sponsor: Industry Sponsor

  Funding: $ 2,550.00

• 564.

  Rick Meeker

  FIV Penetration and Persistence in Neonatal Cat Brain

  9/30/2000 - 9/29/2003

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 72,250.00

• 565.

  Rick Meeker

  FIV Penetration and Persistence in Neonatal Cat Brain

  9/30/2000 - 9/29/2003

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 313.00

• 566.

  Rick Meeker

  FIV Penetration and Persistence in Neonatal Cat Brain

  9/30/2000 - 9/29/2003

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 72,750.00

• 567.

  William Snider; Tushar Patel

  Sensory Neurons Development in the Absence of NGF

  6/1/2000 - 5/31/2003

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 44,212.00

• 568.

  William Snider

  Sensory Neuron Development in the Absence of NGF

  6/1/2000 - 5/31/2003

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 33,832.00

• 569.

  William Snider

  Sensory Neuron Development in the Absence of NGF

  6/1/2000 - 5/31/2003

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 1,000.00

• 570.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 7,000.00

• 571.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 7,517.00

• 572.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 7,000.00

• 573.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 8,199.00

• 574.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,600.00

• 575.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 4,829.00

• 576.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 2,237.00

• 577.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,785.00

• 578.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 4,140.00

• 579.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,010.00

• 580.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,130.00

• 581.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 505.00

• 582.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 5,533.00

• 583.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,515.00

• 584.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 585.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,635.00

• 586.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 587.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,500.00

• 588.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 4,400.00

• 589.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,515.00

• 590.

  Bob Greenwood

  Evaluation eff & tolerability levetriactam add-on treatment in refractory pediatric patients w/ partial seizures: 28-wk double-blind, placebo-control

  5/11/2000 - 12/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,515.00

• 591.

  Rick Meeker

  Choroid plexus macrophages in lentiviral neuropathogenesis: Student Intern Award

  4/28/2000 - 4/27/2001

  Sponsor: Elizabeth Glaser Pediatric AIDS Foundation (EGPAF)

  Funding: $ 2,000.00

• 592.

  Rick Meeker

  Choroid plexus macrophages in lentiviral neuropathogenesis: Student Intern Award

  4/28/2000 - 4/27/2001

  Sponsor: Elizabeth Glaser Pediatric AIDS Foundation (EGPAF)

  Funding: $ 2,000.00

• 593.

  Michael Tennison

  An Open Label, Uncontrolled, Long-Term Study to Assess The Safety of Lamictal in Pediatric Subjects Who Have Previously Taken Part in Study Lam2000

  4/24/2000 - 8/24/2003

  Sponsor: Industry Sponsor

  Funding: $ 5,000.00

• 594.

  Michael Tennison

  An Open Label, Uncontrolled, Long-Term Study to Assess The Safety of Lamictal in Pediatric Subjects Who Have Previously Taken Part in Study Lam2000

  4/24/2000 - 8/24/2003

  Sponsor: Industry Sponsor

  Funding: $ 1,156.00

• 595.

  Michael Tennison

  Protocol LAM 20006:Double-Blind Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics & Efficacy of Lamictal in Pediatric Age...

  4/24/2000 - 8/24/2003

  Sponsor: Industry Sponsor

  Funding: $ 5,000.00

• 596.

  Michael Tennison

  Protocol LAM 20006:Double-Blind Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics & Efficacy of Lamictal in Pediatric Age...

  4/24/2000 - 8/24/2003

  Sponsor: Industry Sponsor

  Funding: $ 7,436.00

• 597.

  Michael Tennison

  Protocol LAM 20006:Double-Blind Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics & Efficacy of Lamictal in Pediatric Age...

  4/24/2000 - 8/24/2003

  Sponsor: Industry Sponsor

  Funding: $ 2,697.00

• 598.

  Bob Greenwood; Ibrahim Elsyed Hassan Elmenshawi

  Fellow; Ibrahim Elmenshawi--Intractable Epilepsy: Clinical and Radiological Study

  3/8/2000 - 3/7/2002

  Sponsor: Embassy of the Arab Republic of Egypt

  Funding: $ 10,201.00

• 599.

  Bob Greenwood; Ibrahim Elsyed Hassan Elmenshawi

  Fellow; Ibrahim Elmenshawi--Intractable Epilepsy: Clinical and Radiological Study

  3/8/2000 - 3/7/2002

  Sponsor: Embassy of the Arab Republic of Egypt

  Funding: $ 10,201.00

• 600.

  Bradley Vaughn

  IRB#00-NEUR-50 - LAM 30004 A Retrospective Genetic Case - Control Study of Serious Rash & Hypersenitivity Syndrome with ....

  1/1/2000 - 12/31/2000

  Sponsor: Industry Sponsor

  Funding: $ 140.00

• 601.

  Bradley Vaughn

  IRB#00-NEUR-50 - LAM 30004 A Retrospective Genetic Case - Control Study of Serious Rash & Hypersenitivity Syndrome with ....

  1/1/2000 - 12/31/2000

  Sponsor: Industry Sponsor

  Funding: $ 285.00

• 602.

  John Mann

  An 8-week, randomized, double-blind, pacebo-controlled, monotherapy of pregabalin for treatment of chronic low back pain

  8/11/1999 - 8/10/2000

  Sponsor: North Carolina Children's and Young Adults' Clinical Research Foundation

  Funding: $ 13,744.00

• 603.

  John Mann

  An 8-week, randomized, double-blind, pacebo-controlled, monotherapy of pregabalin for treatment of chronic low back pain

  8/11/1999 - 8/10/2000

  Sponsor: North Carolina Children's and Young Adults' Clinical Research Foundation

  Funding: $ 1,749.00

• 604.

  John Mann

  An 8-week, randomized, double-blind, pacebo-controlled, monotherapy of pregabalin for treatment of chronic low back pain

  8/11/1999 - 8/10/2000

  Sponsor: North Carolina Children's and Young Adults' Clinical Research Foundation

  Funding: $ 1,600.00

• 605.

  John Mann

  1008-033-428 Preqabalin Open Label, Extension Safety Trial in Patients with Chronic Pain (LBP)

  8/11/1999 - 8/10/2000

  Sponsor: North Carolina Children's and Young Adults' Clinical Research Foundation

  Funding: $ 400.00

• 606.

  John Mann

  1008-033-428 Preqabalin Open Label, Extension Safety Trial in Patients with Chronic Pain (LBP)

  8/11/1999 - 8/10/2000

  Sponsor: North Carolina Children's and Young Adults' Clinical Research Foundation

  Funding: $ 800.00

• 607.

  Albert Hinn

  PRTCL:SB214857/030-Blockade of GP IIB/IIIA Receptor To Avoid Vascular Occlusion (Bravo)

  3/29/1999 - 3/14/2001

  Sponsor: Industry Sponsor

  Funding: $ 13,958.00

• 608.

  William Snider

  GDNF and Synaptic Competition and Maintenance

  7/6/1998 - 4/30/2006

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 417,694.00

• 609.

  William Snider

  GDNF and Synaptic Competition and Maintenance

  7/6/1998 - 4/30/2006

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 420,532.00

• 610.

  William Snider

  The Role of GDNF in Synaptic Competition and Maintenance

  7/6/1998 - 6/30/2003

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 476,731.00

• 611.

  William Snider

  The Role of GDNF in Synaptic Competition and Maintenance

  7/6/1998 - 6/30/2003

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 88,556.00

• 612.

  William Snider

  The Role of GDNF in Synaptic Competition and Maintenance

  7/6/1998 - 6/30/2003

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 265,664.00

• 613.

  William Snider

  The Role of GDNF in Synaptic Competition and Maintenance

  7/6/1998 - 6/30/2003

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 362,444.00

• 614.

  William Snider

  The Role of GDNF in Synaptic Competition and Maintenance

  7/6/1998 - 6/30/2003

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 370,686.00

• 615.

  Bob Greenwood

  Cognition and Brain Development in NF1 Children

  5/15/1998 - 4/30/2004

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 709,552.00

• 616.

  Bob Greenwood

  Cognition and Brain Development in NF1 Children

  5/15/1998 - 4/30/2004

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 147,604.00

• 617.

  Bob Greenwood

  Cognition and Brain Development in NF1 Children

  5/15/1998 - 4/30/2004

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 304,979.00

• 618.

  Bob Greenwood

  Cognition and Brain Development in NF1 Children

  5/15/1998 - 4/30/2004

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 292,931.00

• 619.

  Fulton Crews; Joyce Besheer; Charlotte Boettiger; George Breese; Michael Chua; Sara Faccidomo; James Garbutt; Bob Gwyther; Clyde Hodge; Thomas Kash; Darin Knapp; C.J. Malanga; A Leslie Morrow; Shonagh O'Leary-Moore; Liya Qin; Donita Robinson; Garret Stuber; Kathleen Sulik; Todd Thiele

  Molecular and Cellular Pathogenesis in Alcoholism

  12/1/1997 - 11/30/2017

  Sponsor: NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  Funding: $ 1,838,975.00

• 620.

  William Snider

  Research Training in the Neurosciences

  9/30/1997 - 6/30/2014

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 413,256.00

• 621.

  William Snider

  Research Training in the Neurosciences

  9/30/1997 - 6/30/2014

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 417,922.00

• 622.

  Joseph Piven; Aysenil Belger; Margaret Burchinal; Franc Donkers; Hongbin Gu; Sheryl Moy; Cynthia Powell; Bahjat Qaqish; Steve Reznick; Myra Roche; John Sideris; Debra Skinner; William Snider; Martin Styner; Kinh Truong; Anne Wheeler; Fred Wright

  UNC Developmental Disabilities Research Center

  8/1/1997 - 6/30/2014

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 2,645,692.00

• 623.

  Colin Hall; Ronald Helms; Kevin Robertson

  Neuroimaging in HIV Infection

  4/1/1997 - 9/30/2004

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 1,005,853.00

• 624.

  Colin Hall; Ronald Helms; Kevin Robertson

  Neuroimaging in HIV Infection

  4/1/1997 - 9/30/2004

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 266,177.00

• 625.

  William Snider

  Reversible cell type specific disruption of ERK signaling in developing cortex

  4/7/1993 - 3/31/2017

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 400,803.00

• 626.

  William Snider

  Roles of Growth Factor Signaling in Neural Regeneration

  4/7/1993 - 3/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 345,563.00

• 627.

  William Snider

  Roles of Growth Factor Signaling in Neural Regeneration

  4/7/1993 - 3/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 345,563.00

• 628.

  William Snider

  Roles of Growth Factor Signaling in Neural Regeneration

  4/7/1993 - 3/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 345,563.00

• 629.

  William Snider

  Roles of Growth Factor Signaling in Neural Regeneration

  4/7/1993 - 3/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 114,093.00

• 630.

  William Snider

  Roles of Growth Factor Signaling in Neural Regeneration

  4/7/1993 - 3/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 476,915.00

• 631.

  William Snider

  Roles of Growth Factor Signaling in Neural Regeneration

  4/7/1993 - 3/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 469,553.00

• 632.

  William Snider

  RAF/MEK/ERK Regulation of Axon Growth and Differentiation

  4/7/1993 - 3/31/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 403,325.00

• 633.

  William Snider

  RAF/MEK/ERK Regulation of Axon Growth and Differentiation

  4/7/1993 - 3/31/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 399,255.00

• 634.

  William Snider

  RAF/MEK/ERK Regulation of Axon Growth and Differentiation

  4/7/1993 - 3/31/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 407,148.00

• 635.

  William Snider

  RAF/MEK/ERK Regulation of Axon Growth and Differentiation

  4/7/1993 - 3/31/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 411,131.00

• 636.

  William Snider

  RAF/MEK/ERK Regulation of Axon Growth and Differentiation

  4/7/1993 - 3/31/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 381,292.00

• 637.

  William Snider

  RAF/MEK/ERK Regulation of Axon Growth and Differentiation

  4/7/1993 - 3/31/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 29,904.00

• 638.

  William Snider

  RAF/MEK/ERK Regulation of Axon Growth and Differentiation (ARRA)

  4/7/1993 - 9/14/2011

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 175,414.00

• 639.

  Stephen Hooper; Grace Baranek; Elaine Coonrod; Robert Greenwood; Deborah Hatton; Barbara Leach; Daniel Moran; Cynthia Powell; Rebecca Pretzel; Debra Reinhartsen; Angela Rosenberg; Jackson Roush; Linmarie Sikich

  North Carolina - LEND/AE

  7/1/1990 - 6/30/2016

  Sponsor: Maternal and Child Health Bureau

  Funding: $ 200,000.00

• 640.

  Rick Meeker

  Excitatory Amino Acid Regulation of Vasopressin Cells

  7/1/1977 - 5/31/2002

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 602,179.00

• 641.

  Rick Meeker

  Excitatory Amino Acid Regulation of Vasopressin Cells

  7/1/1977 - 5/31/2002

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 117,570.00

• 642.

  Jim Beck; Roland Arnold; Ikramuddin Aukhil; Arthur Aylsworth; Albert Baldwin; Stephen Bayne; John Buse; Jianwen Cai; Daniel Caplan; Catherine Champagne; Myron Cohen; Lyndon Cooper; Luda Diatchenko; Greg Essick; Eric Everett; Ronald Falk; Rosann Farber; Patrick Flood; Sylvia Frazier-Bowers; John Gilmore; Susan Girdler; Gerardo Heiss; Alan Hinderliter; Mark Hollins; Robert Johnston; Jay Kaufman; Thomas Kawula; Jessica Lee; Kathleen Light; Nobuyo Maeda; Terry Magnuson; William Maixner; Glenn Matsushima; Robert Millikan; Timothy Nichols; Steven Offenbacher; Andrew Olshan; David Paquette; Leslie Parise; Dhavalkumar Patel; Lauren Patton; Ceib Phillips; Cynthia Powell; Nancy Raab-Traub; Estelle Riche; Beverly Rockhill; Richard Rozier; Robert Ryder; Ryan Sartor; David Savitz; Victor Schoenbach; Diane Shugars; William Snider; John Stamm; Ronald Strauss; Edward Swift; David Threadgill; Deborah Threadgill; Jenny Ting; Alexander Tropsha; Carroll-Ann Trotman; J F Camilla Tulloch; Don Tyndall; Paul Watkins; David Weber; Jennifer Webster-Cyriaqu; Raymond White; Alan Whitmore; Ray Williams; John Wright; Mitsuo Yamauchi; David Zajac; John Zuniga

  Clinical Research Training in Oral Diseases for Future

  6/30/2012

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 443,559.00

• 643.

  William Snider; Paul Manis

  Research Training in the Neurosciences

  6/30/2014

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 398,221.00

• 644.

  William Snider; Paul Manis

  Research Training in the Neurosciences

  6/30/2014

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 353,334.00

• 645.

  William Snider; Gerry Oxford

  Research Training in the Neurosciences

  6/30/2014

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 333,767.00

• 646.

  William Snider; Gerry Oxford

  Research Training in the Neurosciences

  6/30/2014

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 296,994.00

• 647.

  William Snider; Gerry Oxford

  Research Training in the Neurosciences

  6/30/2014

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 282,516.00

• 648.

  William Snider; Robert Rosenberg

  Research Training in the Neurosciences

  6/30/2014

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 341,178.00

• 649.

  William Snider

  Research Training in the Neurosciences

  6/30/2014

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 408,720.00